

Article

Subscriber access provided by MASARYK UNIV BRNO

Synthesis of an apionucleoside family and discovery of a prodrug with anti-HIV activity.

Kiran S Toti, Marco Derudas, Fabrizio Pertusati, Davy Sinnaeve, Freya Van den Broeck, Lia Margamuljana, Jose C. Martins, Piet Herdewijn, Jan Balzarini, Christopher McGuigan, and Serge Van Calenbergh

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/jo500659e • Publication Date (Web): 07 May 2014

Downloaded from http://pubs.acs.org on May 15, 2014

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Synthesis of an apionucleoside family and discovery of a prodrug with anti-HIV activity

Kiran S. Toti,^a Marco Derudas,^b Fabrizio Pertusati,^b Davy Sinnaeve,^c Freya Van den Broeck,^c Lia Margamuljana,^d José C. Martins,^c Piet Herdewijn,^d Jan Balzarini,^d Christopher McGuigan,^b Serge Van Calenbergh^{a,*}

^a Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium.

^b Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, UK.

^c NMR and Structure Analysis Unit, Department of Organic Chemistry, Ghent University, Krijgslaan 281 S4, B-9000 Ghent, Belgium.

^d Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium.

* Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, UGent, Harelbekestraat 72, B-9000 Gent, Belgium. Phone: +32 9 264 81 24. Fax: + 32 9 264 81 46.
E-mail: serge.vancalenbergh@ugent.be

Graphical Abstract



Abstract

We report the synthesis of a family of D- and L-furano-D-apionucleosides, their 3'deoxy-, as well as their 2',3'-dideoxy-analogues with thymine and adenine nucleobases. Single carbon homologation of 1,2-*O*-isopropylidene-D-glycero-tetrafuranos-3-ulose (**15**) and optimized glycosylation conditions involving microwave irradiation were key to the successful synthesis of the target compounds.

While all target nucleosides failed to show significant antiviral activity, we demonstrated that the triphosphate of 2',3'-deoxy-D-apio-D-furanoadenosine (1), in contrast to that of its D-apio-L-furanose epimer 2, was readily incorporated into a DNA template by HIV reverse transcriptase to act as a DNA chain terminator. This led us to convert adenine derivative 1 into two phosphoramidate prodrugs. ProTide **9b** was found active against HIV-1 and HIV-2 (EC₅₀ = 0.5-1.5 μ M), indicating that the lack of activity of the parent nucleoside

3
4
5
6
7
0
0
9
10
11
12
13
14
15
16
17
17
18
19
20
21
22
23
24
25
26
20
21
28
29
30
31
32
33
34
35
36
30
31
38
39
40
41
42
43
44
45
75 76
40 17
47
48
49
50
51
52
53
54
55
55
00
5/
58
59

60

and possibly also other members of the D-apio-D-furanose nucleoside family must be sought in the inefficient cellular conversion to the monophosphate.

Keywords: Apionucleosides, ProTides, antivirals, RT inhibitor, microwave synthesis,

nucleoside triphosphate.

Introduction

Although the pharmacological scope of nucleoside analogues is still expanding, they remain most renowned for their utility as antiviral drugs [1]. 2',3'-Dideoxy- β -D-apio-D-furanonucleosides (D-ddANs, **1**, Figure 1) were synthesized in the early 1990s as potential antiviral agents, but were found inactive [2,3,4]. However, some of us recently discovered that the 3'-*O*-phosphonomethylated adenine (A) and thymine (T) analogues **7** exhibit promising anti-HIV properties [5]. Since these phosphonates act as bioisosteres of the phosphorylated species **8**, we decided to reinvestigate the biological activity of these ddANs. We envisioned a synthetic approach that would also give access to the known apionucleosides **3** [6,7], their 3'-deoxy counterparts **2** [8,9,10,11], and inadvertently also the D-apio-L-furanose epimers **4-6**. Furthermore, we planned to expand the potential of the 2',3'-dideoxyapio nucleosides **1** and **4** as antiviral agents by synthesizing their phosphoramidate prodrugs **9**, **10** and **11**. These would lead to the intracellular release of the parent nucleotides like **8** [12, 13], thereby by-passing the often problematic first phosphorylation step in the conversion to the active triphosphate species [14].







Page 6 of 61

Results and Discussion

Chemistry



Scheme 1. Synthesis of the D- and L-furano-D-apiose coupling partners 17 and 24 and their 3-deoxy analogues 19, 20 and 28. *Reagents and conditions*: (a) TEMPO, BAIB, CH₂Cl₂, rt, 3-4h, 90%; (b) BOMSnBu₃, n-BuLi, THF, -78 °C, 2h, 68%; (c) (i) 80% aq. AcOH, 80 °C, 8h; (ii) Ac₂O, DMAP, pyridine, 55 °C, 16h, 75%; (d) (i) NaH, CS₂, MeI, THF, 0 °C \rightarrow rt, 1h; (ii) Et₃B, Bu₃SnH, toluene, rt, 3-4h, 68%; (e) (i) 80% aq. AcOH, 80 °C, 8h; (ii) Ac₂O, DMAP, rt, pyridine, 4h, 57%; (f) (i) *p*-TsOH (*para*-toluenesulfonic acid), MeOH, rt, overnight; (ii) Ac₂O, DMAP, pyridine, 0 °C \rightarrow rt, 4h, 77%; (g) CH₃COOH-H₂O (2:1), rt, 3 days, 83%; (h) Bu₂SnO, toluene, 140 °C, 2h, TBAB, BnBr, 100 °C, 18h, 94%; (i) H₂, Pd/C, MeOH, rt, 5h, 90%; (j) acetone, conc. H₂SO₄, rt, 1.5h, Na₂CO₃, 45 min, 73% (after 3 cycles); (k) DMF, NaH, 0 °C, 10 min, BnBr, 0 °C \rightarrow rt, 18h, 95%; (l) (i) 80% aq. AcOH,

The Journal of Organic Chemistry

Compounds 16 and 27 were considered valuable intermediates to access the envisaged family of D-furanoapionucleosides (Scheme 1). They were prepared from 1,2-isopropylidene- α -Lthreose (14), which was obtained in six steps from L-ascorbic acid [15,16]. Interestingly, screening of different oxidation methods [15,17,18] to convert 14 to ketone 15 indicated that TEMPO-BAIB ([Bis-(acetoxy)-iodo]benzene) oxidation, best known for oxidation of primary hydroxyl groups, was the most effective. Conversion of 15 to 16 is feasible by reacting the former with diazomethane to give a spiro-oxirane [19], which can then be opened with benzylalkoxide to give 16 [20]. To avoid the use of diazomethane, we explored several variations of the polarity reversal concept to realize the desired carbon homologation. Reaction with benzyloxymethyl chloride in the presence of samarium iodide did not yield the desired product, while the corresponding Grignard reaction gave 16 in disappointing yields [21]. Nucleophilic attack of the ketone with lithiated benzyloxymethyltributyltin afforded 16 in acceptable yield [22], considering the propensity of compound 15 to undergo selfcondensation to the aldol dimer [23]. The NMR spectra of 16 were in accordance with reported data [20] and C-3 stereochemistry was further confirmed by a two-dimensional (2D) ¹H-¹H NOESY experiment. One-pot acid hydrolysis and acetylation of **16** gave the triacetylated apiose 17 in a 2:1 α/β anomeric ratio.

Jin *et al.* reported the conversion of 23 to 27 using Barton-McCombie deoxygenation (BMD) [18]. Surprisingly, BMD of 16 afforded 18 instead of 27. This led us to reinvestigate the protocol of Jin *et al.* on compound 23, prepared from the commercially available 21 [24]. In our hands BMD on 23 also gave 18. The stereochemistry was confirmed by 2D 1 H- 1 H NOESY experiment and by independent synthesis of compound 27. The formation of 18 is explained by radical quenching from the least hindered face, *i.e.* opposite to the isopropylidene comprising face [25]. Furthermore, Jin *et al.* probably synthesized the enantiomer of 18, since they started from D-galactose, which should lead to 1,2-*O*-

isopropylidene- α -D-threofuranose (i.e., the enantiomer of 14 [15]). Compound 23 was hydrolyzed and acetylated to give the L-furano analogue of triacetylated apiose 24.

Compound **18** was hydrolyzed and acetylated to give **19** in a 4:1 (β : α) anomeric ratio. The anomeric configuration was inferred from the anomeric proton coupling constants, *i.e.* 0 Hz for the β -isomer and 4.4 Hz for the α -isomer. However, this conversion lacked reproducibility, especially on a larger scale. To overcome this problem, the methyl anomer **20** was synthesized in two steps from **18**. Since the coupling constant for anomeric hydrogen is close to 0 Hz, **20** is assumed to be the β -isomer.

Carey and co-workers found that 1,2-*O*-isopropylidine-L-furano-D-apiose **22** equilibrates into a mixture of the D- and L-furanose form in acidic acetone, which inspired us to use similar conditions for the epimerization of **25** [19]. We hypothesized that the absence of the 3-hydroxyl group would eliminate the repulsive dipole interaction with oxygen at position 2, while the steric interaction of the hydroxymethyl group with the 2-oxygen could result in a favorable D-furano isomer ratio. Hence compound **18** was debenzylated and then equilibrated in acetone-conc.H₂SO₄ to isolate the desired compound **26** in 73% yield after 3 equilibrium cycles. Benzylation of **26** gave **27**, which upon hydrolysis and acetylation rendered 3-deoxy-D-apio-D-furanose derivative **28** in good yields.

Having the coupling synthons 17, 19, 20, 24 and 28 in hand, we set out different coupling reaction conditions for 19 and 20 with silvlated thymine or N^6 -benzoyladenine under Vorbrüggen conditions (Table 1).



^c two diastereomers observed by TLC and HRMS analysis.

^d 0.2 equivalents of TMSOTf.

^e inseparable 2:1 mixture of **29** and its β -isomer.

Whereas the acetate anomer **19** reacted smoothly at room temperature in 4h with silylated thymine in the presence of TMSOTf to quantitatively give **29**, coupling with N^{6} -benzoyladenine only afforded the desired coupling product **30** in 32% yield by heating the reaction mixture at 40 °C for 48h [26]. This low yield resulted from the formation of an equal amount of an unknown isomer. ¹H-NMR of this isomer suffered from peak broadening and indicated the presence of minor impurities. Its UV ($\lambda_{max} = 331.9$ nm) and ¹³C-spectrum was characteristic of an N¹-isomer [27,28]. After treatment with methanolic ammonia for two days, a product was formed that was confidently identified as **31** (Figure 2). The binding topology of the adenine base to the sugar was determined by NMR. A correlation between H-1'and C-2 in a 2D ¹H-¹³C HMBC spectrum indicates that the adenine is either bound via N-1 or N-3. In a 2D ¹H-¹H NOESY spectrum, nOe cross-peaks were detected between the amide

 Table 1. Vorbrüggen coupling conditions.

proton and several protons of the sugar moiety, most notably H-1', H-2' and *ortho*-protons of the benzoyl group. In addition to this, *ortho*-protons of the benzoyl moiety also showed nOe interactions with all up (α -face) protons of the furanose ring. These nOe's are improbable if the base is attached via N-3, since in this case the amide group and the sugar moiety would be positioned *para* relative to one another and be spatially too far apart.

Coupling reaction between methylglycoside 20 and silylated thymine (entries 3 and 4), using either TMSOTf or SnCl₄, resulted in the formation of two main products that gave spots with comparable intensity on TLC. ESI-HRMS analysis allowed identifying these products as the two diastereomers of [18, 29]. The condensation reaction of methylglycoside with silylated benzoyladenine in the presence of anhydrous SnCl₄ gave an unresolvable reaction mixture.



Figure 2. Byproducts (or their deprotected form) formed during Vorbrüggen coupling

Vorbrüggen coupling of the methyl anomer **20** and silylated thymine under microwave irradiation resulted in an inseparable mixture of two isomeric products in a 2:1 ratio [30], even after removal of the acetyl and benzyl protecting groups. The ¹H-NMR spectrum of the minor isomer **33** showed a larger splitting of the anomeric hydrogen doublet (3.2 Hz) compared to the major compound (2.0 Hz), indicating a β -oriented pyrimidine moiety. The gHMBC confirmed the C1'-N1 attachment, while 2D NOESY ratified the relative stereochemistry.

The Journal of Organic Chemistry

Conversely, microwave-assisted coupling between **20** and silylated N^6 -benzoyladenine gave only the desired α -nucleoside **30** in 60% isolated yield. Clearly, the microwave-assisted coupling with the methyl glycoside is the method of choice to prepare the adenine nucleoside.



Scheme 2. Synthesis of α -L-furano-D-apionucleosides **6a,b** and their 3'-deoxy counterparts **5a,b**. *Reagents and conditions*: (a) appropriate silylated base, 1,2-(CH₂)₂Cl₂, TMSOTf, rt, 4h, 85% for **34**; (b) appropriate silylated base, CH₃CN, 0.2 eq. TMSOTf, microwave (MW) 300W, 0 °C \rightarrow 150 °C, 3 min, 150 °C, 5 min, 40% for **35** and 6% for **36**; (c) NH₃, MeOH, rt, 4-48h, 75-96%; (d) H₂, Pd/C, MeOH, rt, overnight, 86% for **5a** from **37** and 71% for **6a** from **39**;(e) (i) Pd(OH)₂, HCOOH-MeOH (1:1 for **5b**, **41** from **38**/1:9 for **6b** from **40**), 55 °C, 5-8h; (ii) NH₃, MeOH, rt, 3h, 80% over two steps for **5b** and **6b**.

Reaction of the triacetyl apiose 24 with silylated thymine under classical Vorbrüggen conditions provided 34 in very good yield (Scheme 2). Microwave conditions were employed to couple 24 with silylated N^6 -benzoyladenine, affording 35 and minor amounts of the 2'-OTMS analogue 36. The coupling products 29, 30, 34 and 35 were treated with ammonia in methanol to provide the desired deacetylated products 37-40. Debenzylation of L-furano-D-apio thymine nucleosides 37 and 39 to give the 3'-deoxyapionucleoside 5a and

apionucleoside **6a** was realized by Pd-catalyzed hydrogenation. The same reaction condition on adenosines **38** and **40** was ineffective, as well as the use of cyclohexene and ammonium formate. This led us to use formic acid as hydrogen source to give **5b** and **6b**. The byproduct **41** was converted to **5b** upon treatment with ammonia in methanol.



Scheme 3. Synthesis of β -D-furano-D-apionucleosides. *Reagents and conditions:* (a) silylated thymine, 1,2-(CH₂)₂Cl₂, TMSOTf, rt, 4h; (b) silylated *N*⁶-BzA, CH₃CN, 0.2 eq. TMSOTf, MW 300W, 0 °C \rightarrow 150 °C, 3 min, 150 °C, 5 min; (c) 7N NH₃-MeOH, rt, 4-48h, 46-97% over two steps, 28% for 43 and 11% of its α -anomer; (d) for 42 and 48, H₂, Pd/C, MeOH, rt, 4h, 86-89%; (e) (i) Pd(OH)₂, HCOOH-MeOH (1:4), 55 °C, 5h (ii) NH₃, MeOH, rt, 3h, 89% for 2b and 3b; (f) thiocarbonyl diimidazole, DMF, 80 °C, 90 min, 89% for 46 and 78% for 47; (g) P(OCH₃)₃, 120 °C, 6h, 90%.

Using similar protocols **17** and **28** were converted to **2a**,**b** and **3b** in acceptable yields (Scheme 3). Compared to the L-series, this sequence gave low yields for both thymine and adenine analogues, in particular for the 3'-deoxy analogues. Moreover, coupling of **28** with silylated benzoyladenine produced significant amount of α -isomer (11%), possibly due to participation of the 3'-benzyloxymethyl group, with only 28% of desired β -nucleoside. Since the synthesis of **1a**,**b** via **28** involves many linear steps, we envisaged more convenient access

The Journal of Organic Chemistry

to 2',3'-dideoxy-β-D-apio-D-furanonucleosides **1a,b** involving Corey-Winter olefination [31] and stereoselective hydrogenation as key steps. During catalytic hydrogenation the *syn*-addition of the hydrogen atoms to the double bond is anticipated to occur from the face opposite to the nucleobase [32]. Thiocarbonylation of **44** and **45** using thiocarbonylimidazole provided precursor compounds **46** and **47** for Corey-Winter olefination. Unfortunately, the adenine derivative degraded in trimethylphosphite at 120 °C. The thymine derivative gave the desired product **48** in excellent yield but the hydrogenation reaction resulted in a mixture of diastereomers **1a** and **4a** that were inseparable by column chromatography. This forced us to follow the classical route *via* **2a,b** to the target 2',3'-dideoxy analogues.

Initially, the benzyl protected nucleosides **37** and **38** were subjected to a standard Barton-McCombie protocol to give the 2'-deoxygenated products **53** and **54** (Scheme 4). Different hydrogen sources were explored for the subsequent Pd-catalyzed debenzylation, but only the thymine compound **53** could be converted to the desired product **4a** with curtailed reproducibility. This was attributed to catalyst poisoning by remaining sulfur residues. Hence, we swapped to TBS as a protecting group to give **49-52** from **5a,b** and **2a,b** in excellent yields. Compounds **49-52** were submitted to BMD after conversion to the corresponding xanthates with p-tolylchlorothionoformate in the presence of DMAP. These xanthates were isolated after a brief workup and heated in toluene with tributyltin hydride and azobisisobutyronitrile to give the 2',3'-dideoxyapiose nucleosides **55-58**. The TBS group of **55** and **56** was removed using TBAF in THF. However, the removal of the tetrabutylammonium salt to get pure adenosine derivative **4b** was not satisfactory, hence we used NH₄F in methanol at 55 °C for 2 days to give **4a,b** and **1a,b** in excellent isolated yields [33].



Scheme 4. Synthesis of D- and L-furano-D-dideoxydihydroapionucleosides. *Reagents and conditions*: (a) TBSCl, imidazole, DMF, rt, overnight, 82-95%; (b) (i) *p*-tolylchlorothionoformate, DMAP, ACN, 0 °C \rightarrow rt, 4h; (ii) Bu₃SnH, AIBN, toluene, reflux, 2-3h, 70-90% over two steps; (c) H₂/Pd-C, methanol, rt, overnight, 53 to 4a, 63%; (d) TBAF, THF, rt, 3h, 55 to 4a, 89%; (e) NH₄F, MeOH, 50 °C, 2 days, 86-94%.

To examine the potential of their monophosphate prodrugs as anti-HIV agents, apiodideoxynucleosides **1b** and **4b** were converted to the corresponding triphosphates **12** and **13**, following the method of Caton-Williams (Scheme 5) [34]. The yield of the D-isomer **12** was low and ¹H NMR indicated internal salt formation. Likewise, the ³¹P NMR of this compound is uncharacteristic of triphosphate salts, as it showed two broad peaks. The addition of two equivalents of triethylamine disrupted this internal salt leading to the appearance of the characteristic triphosphate peaks (See supporting information).



Scheme 5. Synthesis of D- and L-furano-D-dideoxyapioadenosine triphosphates (D-/LddAATP) 12 and 13. *Reagents and conditions:* (a) 59, 60, n-Bu₃N, anh. DMF, rt, 1.5h; (b) (i) 1b/4b, anh. DMF, rt, 1.5h; (ii) I₂, rt, 20 min, H₂O, rt, 1.5h, 21% for 12 and 48% for 13.

Nucleoside monophosphate prodrugs (ProTides), featuring an alanine as the preferred amino acid [35,36,37], were prepared using two different methods (Scheme 6) [38]. The thymine analogue **11a** was prepared by coupling **4a** with the phosphorochloridate **64a**, using *tert*-butylmagnesium chloride as hydroxyl activator. Under similar reaction conditions compound **4b** degraded. Hence, all other analogues were coupled with **64a/b** using Nmethylimidazole (NMI) as a base in a mixture of anhydrous THF and pyridine as solvents. In all cases, the desired compounds were obtained as a mixture of two diasteroisomers resulting from the two possible configurations of the phosphorous stereo center, as confirmed by the presence of two equal height peaks in the ³¹P-NMR spectrum.



Scheme 6. Synthesis of apionucleoside ProTides. *Reagents and conditions:* (a) CH₂Cl₂, TEA, -78 °C, 30 min, rt, 2h, 87-96%; (b) *t*-butyl magnesium chloride, THF, rt, overnight, 22% for **11a**; (c) NMI, THF, pyridine, rt, 2 days, 15-88%.

DNA Chain termination study using HIV Reverse Transcriptase

A prerequisite for ProTides to show a good biological profile is that the corresponding triphosphates are good substartes for the final target, such as reverse transcriptase (RT) for HIV. Hence we investigated the ability of triphosphates **12** and **13** to act as a substrate of HIV-RT in a primer-template assay [39]. The template has overhanging T residues to test incorporation of the modified A nucleotide. Figure 3 clearly shows that both nucleotides **12** and **13** function as DNA chain terminators. The D-furano analogue **12** is more efficiently

incorporated than its 3'-epimer **13**, but compared to natural substrate 2'-deoxyadenosine triphosphate (dATP), requires a higher concentration and longer time for complete incorporation. The characteristics of **12** towards HIV RT render the corresponding ProTides as potentially useful HIV inhibitors.



Figure 3. Electrophoregram that shows DNA chain termination through incorporation of dideoxydihydro-D-apio-D-furano-adenosine triphosphate (12) and dideoxydihydro-D-apio-L-furano-adenosine triphosphate (13) by HIV RT. The DNA polymeration mixtures containing 125 nM annealed (labeled) primer-template complex, were treated with 125, 500, or 1000 μ M of modified triphosphate (12/13) and 0.03 U. μ l⁻¹ HIV RT and incubated at 37°C. Aliquots were taken after 15, 30 and 60 min. In the control reaction, 50 μ M of natural dATP was used. Samples were separated on a 0.4 mm 20% denaturing polyacrylamide gel and the bands visualized using phosphorimaging.

Enzymatic assay using carboxypeptidase Y

The putative mechanism of activation of ProTides [40, 41, 42] (Figure 4) involves an enzymatic cleavage of the ester (step **a**) mediated by an esterase- or carboxypeptidase-type enzyme followed by spontaneous cyclisation with releasing the phenolate anion (step **b**) and to open the unstable mixed anhydride ring by water (step **c**) providing the intermediate

metabolite (D/L) **67a/b**. The cleavage of the phosphorous-nitrogen bond of the latter (step d) requires a phosphoramidase-type enzyme, perhaps related to human HINT-1, to release the monophosphate form (D-/L- **68 a/b**).



Figure 4. Putative mechanism of bioactivation for monophosphate prodrugs.

In order to investigate this mechanism of bioactivation for ProTides **9a** and **11a**,**b**, we performed an enzymatic experiment incubating the compounds with carboxypeptidase Y enzyme in acetone- d_6 and Trizma buffer (pH = 7.6) recording a ³¹P-NMR at specific time intervals. The L-furano series displayed pronounced difference in rate of hydrolysis among two diastereomers, a phenomenon that was observed earlier for ProTides of phosphates [38] and phosphonates [43]. For instance, one of the diastereoisomer of **11a** (³¹P-NMR = 3.3 ppm, Figure 5, panel A) seems to be more slowly converted compared to the other. In fact, after 18h, it is still present, even after the addition of an extra portion of enzyme, while the diastereomer at 3.5 ppm appears fully converted after about 10 minutes. In contrast, compound **11b** (³¹P-NMR = 3.2 and 3.4 ppm, Figure 5, panel B) shows a near complete conversion of both diasteroisomers to the metabolite L-**67b** (³¹P-NMR = ~7.0 ppm) through the intermediate L-**65b** (³¹P-NMR = ~4.5 ppm) after 1 hour, although there again exists a clear difference in kinetics.



Figure 5. ³¹P-NMR stack spectra for bioactivation study of compounds 11a (panel A) and 11b (panel B) using carboxypeptidase Y enzyme. The assignment of the resonance signals to the indicated metabolites was done in analogy with previous studies [35].

Within 20 minutes after addition of the enzyme compound **9a** (31 P NMR = 3.5 and 3.7 ppm) was completely converted to the intermediate metabolite D-**65a** (31 P-NMR = 4.5 and 4.8 ppm), which was fully converted to compound D-**67a** (31 P-NMR = ~7.1 ppm) within an hour (Figure 6). In this case no pronounced diastereomeric discrimination by carboxypeptidase

enzyme was observed. Following the trend for adenine analogue **11b**, we assume that **9b** would be processed at the least with the rate of thymine analogue **9a**.



Figure 6. ³¹P-NMR stack spectra for bioactivation study of compound **9a** using carboxypeptidase Y enzyme. The assignment of the resonance signals to metabolites D-**65a** and D-**67a** is based on LC-MS experiments.

From this study it is evident that both D- and L-furanonucleoside ProTides are readily converted to the intermediate metabolite **67**.

Biological Evaluation

The 2',3'-dideoxy analogues **1a**,**b** and the 3'-deoxy- β -D-apio-D-furanonucleosides **2a**,**b** failed to show both activity against HIV-1,2 and cytotoxicity. Likewise, the 2',3'-dideoxy analogues **4a**,**b** and the 3'-deoxy- β -D-apio-L-furanonucleosides **5a**,**b** lacked significant activity against HIV-1 and HIV-2 and a panel of other DNA and RNA viruses,

and were also devoid of cytotoxicity. The thymine-based ProTides **9a** and **10a** were also devoid of anti-HIV activity, which might be due to inefficient conversion of the alaninyl dddATMP to the corresponding monophosphate by HINT-1-type phosphoramidase enzyme or further kinase mediated conversion to the corresponding triphosphate. Alternatively, the latter may be inefficiently incorporated by HIV RT (Table 2).

Interestingly, the 2',3'-dideoxy-D-apio-D-furanoadenosine phosphoramidate ProTides **9b** and **10b** combine potent and moderate anti-HIV activity with reasonable selectivity. The benzylester **9b** exhibits comparable or even somewhat superior anti-HIV activity to the acyclic nucleoside phosphonate *R*-PMPA (tenofovir) [44]. The ProTides **9a,b**, **10a,b** and **11a,b** are weak to moderate inhibitors of murine leukemia (L1210), human T-lymphocyte (CEM) and human cervix carcinoma (HeLa) cell proliferation (Table 3).

	EC ₅₀ in MT-4 cells (µM)			EC ₅₀ in CEM cells (µM)	
	HIV-1	HIV-2 (ROD)	CC ₅₀	HIV-1 (IIIb)	HIV-2 (ROD)
	(NL4.3)				
9a	>250	>250	196	_	-
10a	>250	>250	>250	-	-
9b	0.5	1.0	93	0.5	1.5
10b	26	24	>250	7.5	38
<i>R</i> -PMPA	1.7	1.0	>250	3.0	2.5

Table 2. Antiviral activity and cytotoxicity of ProTides 9a,b and 10a,b

'-' = not performed

Table 3. Cytotoxicity data of ProTides 9a,b and 10a,b^a

	L1210	CEM	HeLa
9a -	113 ± 21	108 ± 11	159 ± 32
9b	110 ± 17	80 ± 4	53 ± 11
10a	>250	> 250	> 250
10b	226 ± 35	204 ± 3	\geq 250
11a	167 ± 85	113 ± 3	177 ± 103
11b	79 ± 4	73 ± 5	173 ± 58

ACS Paragon Plus Environment

^a IC_{50} in μ M, murine leukemia cells (L1210/0), human T-lymphocyte cells (CEM/0) and human cervix carcinoma cells (HeLa)

Conclusion

In this study we report the synthesis of a family of D-apionucleosides comprising the A and T members of both possible 3'-epimers of β -D-apiofuranose nucleosides, as well as their 3'-deoxy and 2',3'-dideoxy analogues. Clues in the synthesis of the desired apionucleosides were a carbon homologation of 1,2-*O*-isopropylidene-D-glycero-tetrafuranos-3-ulose (**15**) and optimized glycosylation conditions involving microwave irradiation. In the course of this work, we rectified some anomalies in the structure assignments reported by others.

In accordance with earlier reports the target D-apio-D-furanose nucleosides failed to show antiviral activity and so did their D-apio-L-furanose epimers. However, the triphosphate of 2',3'-dideoxy- β -D-apio-D-furanoadenosine (12) (in contrast to its D-apio-L-furanose epimer 13) was readily accepted by viral DNA polymerase to act as a DNA chain terminator. This led us to convert the parent A and T nucleosides 1a and 1b into phosphoramidate prodrugs 9 and 10. The A analogues 9b and 10b indeed showed a considerable anti-HIV activity. This indicates that the lack of activity of the parent 2',3'-dideoxy- β -D-apio-D-furanose nucleoside must be the result of inefficient conversion to the monophosphate in the biological assay. This study demonstrates that the large pool of nucleoside analogues that were previously found to lack antiviral activity may contain valuable candidates to be turned into ProTide derivatives exhibiting promising antiviral activity, by efficiently bypassing the first phosphorylation step that is often rate-limiting the intracellular conversion of nucleoside analogues to their bio-active triphosphate derivatives.

Experimental Section

Synthesis

All reagents were from standard commercial sources and of analytic grade. Dry solvents were obtained directly from commercial sources and stored on molecular sieves. All reactions were carried out under argon atmosphere using anhydrous solvents unless specified otherwise. Room temperature or rt refers to 25±5 °C. Silica-gel precoated with F254 plates were used for TLC. The spots were examined under ultraviolet light at 254 nm and further visualized by sulphuric acid-anisaldehyde spray. Column chromatography was performed on silica gel (40-63 µm, 60 Å) or on flash chromatography system. NMR spectra were recorded on a 300 MHz, 500 MHz or 700 MHz spectrometer. Chemical shifts are given in ppm (δ), calibrated to the residual solvent signals or TMS. Exact mass measurements were performed on mass spectrometer equipped with a standard electrospray ionization (ESI) and modular LockSpray TM interface. Samples were infused in a CH₃CN/H₂O (1:1v/v) mixture at 10 mL/min. The microwave reactions were carried out in Milestone MicroSYNTH Advanced Microwave Synthesis Labstation, equipped with 2 X 800 W magnetrons (effective maximum output 1500W pulsed/continuous), an optical fiber temperature sensor, a pressure sensor, in continues power mode in a closed PTFE vessel. NMR signals of sugar protons and carbons are indicated with a prime, and signals of base protons and carbons are given without a prime. A combination of gCOSY, gHSQC and gHMBC was used to assign ¹H and ¹³C peaks, Noesy was used for selected compounds to assign peaks and/or to confirm relative configuration.

3-Oxo-1,2-*O***-isopropylidene-** α **-D-erythrofuranose** (15)^[18]**:** To a solution of compound 14 (1.0 g, 6.24 mmol) in CH₂Cl₂ (12.5 mL) was added bis-acetoxyiodobenzene (BAIB, 2.41 g, 7.5 mmol) followed by (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO, 195 mg, 1.25 mmol) at room temperature under an argon atmosphere. The mixture was stirred at room

temperature for 4h. The contents of the reaction was directly loaded on silica-gel and eluted with 30% EtOAc-hexanes to afford pure product **15** (890 mg, 90%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.35 (s, 3H, CH₃), 1.44 (s, 3H, CH₃), 4.03 (dd, *J* = 4.1, 17.6 Hz, 1H, 4-H), 4.29 (s, 1H, 2-H), 4.32 (dd, *J* = 0.6, 17.6 Hz, 1H, 4-H), 6.02 (d, *J* = 4.4 Hz, 1H, 1-H).

1,2-0-Isopropylidene-5-(*O*-benzyl)-*a*-D-apio-D-furanose (**16**)^[20]: To a stirring solution of benzyloxymethyltributlytin (BOMSnBu₃, 5.93 g, 14.4 mmol) in THF (35 mL) at -78 °C under inert condition, was added dropwise *n*-butyllithium (1.6M in hexanes,19.5 mL, 31.3 mmol) and stirred for additional 1h. To this mixture was then added dropwise a solution of compound **15** (1.9 g, 12.02 mmol) in 10 mL THF and stirred at -78 °C for 3h. The reaction was quenched with saturated NH₄Cl solution and by vigorous stirring. EtOAc (100 mL) was then added to facilitate the layer separation. Organic layer was separated and the aqueous layer was extracted twice with EtOAc (50 mL). Combined organic layers were dried over anhydrous MgSO₄ and evaporated under reduced pressure. The residue was purified by column chromatography eluting with 17% EtOAc-hexanes to afford **16** (2.3 g, 68%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.37 (s, 3H, CH₃b), 1.58 (s, 3H, CH₃a), 2.85 (s, 1H, 3-OHa), 3.46 (d, *J* = 10.3 Hz, 1H, 5-H), 3.56 (d, *J* = 10.3 Hz, 1H, 5-H), 3.71 (d, *J* = 9.1 Hz, 1H, 4-Ha), 3.80 (d, *J* = 9.1 Hz, 1H, 4-Hb), 4.39 (d, *J* = 3.8 Hz, 1H, 2-Hb), 4.54 - 4.71 (m, 2H, CH₂Ph), 5.76 (d, *J* = 4.1 Hz, 1H, 1-Hb), 7.27 - 7.40 (m, 5H, CH₂Ph).

1,2,3-Tri-(*O*-acetyl)-5-(*O*-benzyl)- α/β -D-apio-D-furanose (17)^[45]: A solution of 16 (2.5 g, 8.92 mmol) in 80% aq. acetic acid (25 mL) was stirred at 80 °C for 8h. The reaction mixture was evaporated to give the crude intermediate as syrup. This syrup was dissolved in pyridine (20 mL) and DMAP was added (100 mg) followed by acetic anhydride (10 mL, 106 mmol). The solution was stirred at 55 °C for 16h. Then, the solvent was removed under vacuum and

Page 25 of 61

The Journal of Organic Chemistry

the resulting residue was partitioned between EtOAc and water. Organic layer separated, combined organic layer was washed with brine, dried over sodium sulfate, and evaporated. The residue was purified by silica-gel column chromatography (15-20% EtOAc-hexanes) to yield **17** (2.45 g, 75%) as a colorless oil as a mixture of α + β isomers (2:1). ¹H NMR (300 MHz, CDCl₃) δ ppm 1.96 (s, 3H, major), 2.08 (s, 3H, major), 2.08 (s, 2H, minor), 2.09 (s, 1H, minor), 2.10 (s, 3H, major), 3.75 (d, *J* = 9.7 Hz, 0.47H, minor), 3.89 (d, *J*=10.5 Hz, 1H, major), 3.96 (d, *J* = 9.7 Hz, 0.5H, minor), 4.05 (d, *J* = 10.5 Hz, 1H, major), 4.22 (d, *J* = 10.3 Hz, 1H, major), 4.26 (d, *J* = 10.5 Hz, 0.52H, minor), 4.32 (d, *J* = 10.5 Hz, 0.5H, minor), 4.34 (d, *J* = 10.3 Hz, 1H, major), 4.51 - 4.62 (m, 3H, major & minor), 5.42 (d, *J* = 4.7 Hz, 0.44H, minor), 5.49 (d, *J* = 1.2 Hz, 1H, major), 6.08 (d, *J* = 1.2 Hz, 1H, major), 6.33 (d, *J* = 4.7 Hz, 0.43H, minor), 7.27 - 7.41 (m, 7H, major & minor). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₈H₂₂O₈Na 389.1212; Found 389.1242.

1,2-*O***-Isopropylidene-3-deoxy-5-(***O***-benzyl)-β-D-apio-L-furanose (18)^[18]: To a solution of 16 (3.5 g, 12.5 mmol) in dry THF (75 mL) was added NaH (60% in mineral oil, 1.5 g, 37.45 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 1h. To this mixture were slowly added CS₂ (11.2 mL, 188 mmol) and MeI (24.0 mL, 375 mmol) and stirred at room temperature for 1h. The reaction mixture was evaporated to give crude xanthate. The xanthate was suspended in dry toluene (75 mL), triethylborane (19.0 mL, 19.0 mmol, 1.0 M solution in THF) and** *n***-Bu₃SnH (5 mL, 19.0 mmol) were added at room temperature and the mixture was stirred for further 3h. The reaction mixture was quenched with water, extracted with EtOAc, dried over anhydrous MgSO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (10% EtOAc-hexanes) to give 18** (2.26 g, 68 %) as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.32 (s, 3H, CH₃a), 1.49 (s, 3H, CH₃b), 2.37 - 2.52 (m, 1H, 3-Ha), 3.52 (dd, *J* = 9.2, 7.5 Hz, 1H, 5-H), 3.69 (dd, *J* = 11.3, 8.6 Hz, 1H, 4-Hb), 3.78 (dd, *J* = 9.4, 6.7 Hz, 1H, 5-H), 4.01 (dd, *J* = 8.4, 7.2 Hz, 1H, 4-

Ha), 4.46 - 4.60 (m, 2H, CH₂Ph), 4.65 (t, *J* = 4.1 Hz, 1H, 2-Ha), 5.83 (d, *J* = 3.8 Hz, 1H, 1-Ha), 7.24 - 7.42 (m, 5H, CH₂Ph).

1,2-Di-*O***-acetyl-3-deoxy-5-(***O***-benzyl)-***u***/β-D-apio-L-furanose (19):** A solution of **18** (750 mg, 2.84 mmol) in 80% aq. acetic acid (10 mL) was stirred at 80 °C for 8h. The reaction mixture was evaporated to give the crude intermediate as a syrup. This syrup was dissolved in pyridine (15 mL) and treated with DMAP (50 mg) and acetic anhydride (2.0 mL, 21.2 mmol). The solution was stirred at room temperature for 4h. The solvent was removed under vacuum and the resulting residue was purified by silica-gel column chromatography (20% EtOAchexanes) to yield **19** (500 mg, 57%) as a colorless oil (α:β anomeric ratio 1:4). Major isomer ¹H NMR (300 MHz, CDCl₃) δ ppm 1.94 (s, 3H, Ac), 1.97 (s, 3H, Ac), 2.83 - 2.96 (m, 1H, 3-H), 3.40 (dd, *J* = 9.1, 7.3 Hz, 1H, 5-H), 3.55 (dd, *J* = 9.1, 7.6 Hz, 1H, 5-H), 3.77 (t, *J* = 8.8 Hz, 1H, 4-H), 4.17 (t, *J* = 8.4 Hz, 1H, 4-H), 4.35 - 4.48 (m, 2H, CH₂Ph), 5.20 (d, *J* = 5.0 Hz, 1H, 2-H), 6.02 (s, 1H, 1-H), 7.18 - 7.32 (m, 5H, CH₂Ph). ¹³C NMR (75 MHz, CDCl₃) δ ppm 20.5 (CH₃CO), 21.0 (CH₃CO), 40.1 (3-C), 66.1 (5-C), 70.9 (4-C), 73.3 (CH₂Ph), 76.1 (2-C), 99.7 (1-C), 127.6 (C_o Ph), 127.7 (C_p Ph), 128.4 (C_m Ph), 137.8 (C_{ipso} Ph), 169.4 (CH₃CO), 169.7 (CH₃CO). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₆H₂₀O₆Na 331.1158; Found 331.1152.

1-*O*-**Methyl-2**-*O*-**acetyl-3**-**deoxy-5**-(*O*-**benzyl**)-β-D-**apio-L-furanose** (**20**)^[18]: A solution of **18** (2.26 g, 8.55 mmol) and *p*-TsOH (700 mg, 4.06 mmol) in MeOH (60 mL) was stirred at room temperature for 16h, neutralized with TEA and evaporated. The residue was partitioned between EtOAc and water, organic layer separated, dried over anhydrous MgSO₄ and evaporated. The residue was purified by column chromatography (20-40% EtOAc-hexanes). The intermediate was dissolved in pyridine (15 mL), acetic anhydride (2.4 mL, 25.2 mmol) and DMAP (200 mg, 1.68 mmol) were added at 0 °C and the reaction mixture was stirred at

room temperature for 4h. The reaction mixture was evaporated, and partitioned between EtOAc and 10% aq. KHSO₄. The organic layer was dried over anhydrous MgSO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (15% EtOAc-hexanes) to give **20** (1.85 g, 77%) as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.00 (s, 3H, 2-OAc), 2.88-3.02 (m, 1H, 3-H), 3.34 (s, 3H, 1-OMe), 3.46 (dd, *J* = 9.1, 7.3 Hz, 1H, 5-H), 3.62 (dd, *J* = 9.2, 7.2 Hz, 1H, 5-H), 3.78 (t, *J* = 8.6 Hz, 1H, 4-H), 4.14 (t, *J* = 8.5 Hz, 1H, 4-H), 4.46 (d, *J* = 12.0 Hz, 1H, CH₂Ph), 4.52 (d, *J* = 12.0 Hz, 1H, CH₂Ph), 4.83 (s, 1H, 1-H), 5.16 (d, *J* = 5.3 Hz, 1H, 2-H), 7.27 - 7.39 (m, 5H, CH₂Ph).

1,2-*O***-Isopropylidene-β-D-apio-L-furanose (22)**^[18]: Compound **21** (5.0g, 21.72 mmol) was dissolved in 50 mL of 2:1 acetic acid-water mixture and stirred at room temperature for 3 days. Solvents were evaporated in vacuo and silica gel column chromatography of the residue (50% EtOAc-hexanes) afforded the title compound **22** as a white solid (3.4 g, 83%). ¹H NMR (300 MHz, CDCl₃) δ ppm 1.33 (s, 3H, C(CH₃)₂), 1.51 (s, 3H, C(CH₃)₂), 2.12 (t, *J* = 5.9 Hz, 1H, 5-OH), 2.69 (s, 1H, 3-OH), 3.71 (dd, *J* = 6.3, 11.16 Hz, 1H, 4-H), 3.80 (d, *J* = 9.8 Hz, 1H, 5-H), 3.94 (d, *J* = 9.4 Hz, 1H, 5-H), 3.96 (dd, *J* = 5.4, 7.5 Hz, 1H, 4-H), 4.38 (d, *J* = 3.8 Hz, 1H, 2-H), 5.99 (d, *J* = 3.7 Hz, 1H, 1-H).

1,2-*O***-Isopropylidene-5-**(*O***-benzyl**)-**β-D-apio-L-furanose** (**23**)^[18,20]**:** Compound **22** (3.1 g, 16.3 mmol) and dibutyltin oxide (6.7 g, 26.9 mmol) was dissolved in toluene (120 mL) refluxed at 140 °C for 2h. The reaction mixture was allowed to attain 100 °C then added tetrabutylammonium bromide (2.63 g, 8.15 mmol) and benzyl bromide (3.0 mL, 25.26 mmol). The reaction mixture was stirred at this temperature for 18h. Solvent was evaporated under reduced pressure and the residue purified by silica gel column chromatography (30% EtOAc-hexanes) to afford **23** (4.3 g, 94%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.32 (s, 3H, C(CH₃)₂a), 1.48 (s, 3H, C(CH₃)₂b), 2.76 (d, *J* = 0.9 Hz, 1H, 3-OHa), 3.54 (d,

J = 9.7 Hz, 1H, 5-H), 3.80 (d, *J* = 9.7 Hz, 1H, 5-H), 3.82 (dd, *J* = 9.4, 0.9 Hz, 1H, 4-Ha), 3.88 (dd, *J* = 9.4 Hz, 1H, 4-Hb), 4.35 (dd, *J* = 3.5, 0.9 Hz, 1H, 2-Ha), 4.57 (d, *J* = 12.0 Hz, 1H, PhC*H*₂), 4.64 (d, *J* = 12.0 Hz, 1H, PhC*H*₂), 5.98 (d, *J* = 3.5 Hz, 1H, 1-Ha), 7.27 - 7.42 (m, 5H, *Ph*CH₂).

1,2,3-Tri-(*O*-acetyl)-5-(*O*-benzyl)-β-D-apio-L-furanose (24): Following the procedure described for the synthesis of **17**, (2.5g, 8.92 mmol) of **23** rendered pure product **24** (2.45 g, 75%) as an oil. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.96 (s, 3H, COCH₃), 2.07 (s, 3H, COCH₃), 2.10 (s, 3H, COCH₃), 3.89 (d, J = 10.5 Hz, 1H, 4-H), 4.05 (d, J = 10.3 Hz, 1H, 4-H), 4.22 (d, J = 10.3 Hz, 1H, 5-H), 4.34 (d, J = 10.3 Hz, 1H, 5-H), 4.50 - 4.62 (m, 2H, PhCH₂), 5.49 (d, J = 1.2 Hz, 1H, 2-H), 6.08 (d, J = 1.2 Hz, 1H, 1-H), 7.26 - 7.40 (m, 5H, *Ph*CH₂).

1,2-*O***-Isopropylidene-3-deoxy-β-D-apio-L-furanose** (**25**)^[18]**:** Compound **18** (3.7 g, 14 mmol) was dissolved in methanol (100 mL), to this was added Pd-C (3.7 g, 10% Pd, wet ~50% H₂O). Stream of hydrogen gas was bubbled through the reaction mixture for 5h at room temperature. The catalyst was filtered off and the filtrate concentrated to give crude product which on purification by silica-gel column chromatography (40% EtOAc-hexanes) rendered **25** (2.2 g, 90%) as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.34 (d, *J* = 0.6 Hz, 3H, C(CH₃)₂), 1.53 (s, 3H, C(CH₃)₂), 2.21 (br.s, 1H, 5-OH), 2.34 (ddtd, *J* = 11.4, 6.9, 5.97, 6.0, 4.8 Hz, 1H, 3-H), 3.82 - 3.91 (m, 3H, 4-H & 5-H's), 3.97 (dd, *J* = 8.5, 7.3 Hz, 1H, 4-H), 4.73 (t, *J* = 4.4 Hz, 1H, 2-H), 5.86 (d, *J* = 3.8 Hz, 1H, 1-H).

1,2-O-Isopropylidene-3-deoxy-\alpha-D-apio-D-furanose (26): To a solution of compound **25** (2.2 g, 12.63 mmol) in 400 mL of acetone was added concentrated sulfuric acid (2.2 mL) and the mixture was stirred at room temperature for 1.5h. Then sodium carbonate (14 g) was added and stirred at room temperature for 45 minutes. Inorganic salts were removed by filtration and the filtrate concentrated under reduced pressure to afford oil. TLC indicated the

conversion in favor of required isomer (roughly 2:1). The title compound is slightly polar with respect to starting material (R_f after two runs: 0.35 for **26** and 0.4 for **25**; eluent, 2.5% MeOH in CH₂Cl₂). Silica-gel flash column chromatography (0.5-1.5% MeOH in CH₂Cl₂) afforded title compound and starting material. After three cycles 1.6 g (73%) of **26** was procured as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.31 (d, *J* = 0.6 Hz, 3H, C(CH₃)b), 1.50 (s, 3H, C(CH₃)a), 1.89 (br.s, 1H, 5-OH), 2.36 - 2.46 (m, 1H, 3-H), 3.58 (dd, *J* = 6.6, 3.4 Hz, 2H, 5-CH₂), 3.83 (d, *J* = 9.1 Hz, 1H, 4-Hb), 4.10 (dd, *J* = 8.9, 5.1 Hz, 1H, 4-Ha), 4.60 (d, *J* = 3.5 Hz, 1H, 2-H), 5.81 (d, *J* = 3.8 Hz, 1H, 1-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm 26.2 (C(CH₃)b), 26.8 (C(CH₃)a), 48.1 (3-C), 62.0 (5-C), 68.7 (4-C), 82.3 (2-C), 105.6 (1-C), 111.3 (*C*(CH₃)₂).

1,2-*O***-Isopropylidene-3-deoxy-5-(***O***-benzyl)-α-D-apio-D-furanose (27): To an ice cold solution of 26** (1.6 g, 9.2 mmol) in DMF (30 mL) was added NaH (60% in mineral oil, 0.55g, 13.8 mmol) and then benzyl bromide (1.64 mL, 13.8 mmol) dropwise. The reaction mixture was stirred at room temperature overnight. Methanol (5 mL) was added and stirred for further 30 minutes. The volatile materials were removed under vacuo and the residue was partitioned between ethyl acetate and water. The organic layer was separated, dried over anhydrous Na₂SO₄, evaporated and the residue purified by column chromatography (5-15% EtOAc in hexanes) to afford **27** (2.3 g, 95%) as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.31 (d, *J* = 0.6 Hz, 3H, C(*CH*₃)b), 1.51 (s, 3H, C(*CH*₃)a), 2.56 (td, *J* = 7.5, 5.1 Hz, 1H, 3-Ha), 3.37 (d, *J* = 7.6 Hz, 2H, 5-C*H*₂), 3.83 (d, *J* = 8.8 Hz, 1H, 4-Hb) 4.09 (dd, *J* = 8.9, 5.1 Hz, 1H, 4-Ha) 4.51 (d, *J* = 3.2 Hz, 2H, PhCH₂), 4.56 (d, *J* = 3.5 Hz, 1H, 2-Hb), 5.79 (d, *J* = 3.5 Hz, 1H, 1-Hb), 7.27 - 7.41 (m, 5H, *Ph*CH₂). ¹³C NMR (75 MHz, CDCl₃) δ ppm 26.3 (C(*C*H₃)b), 26.9 (C(*C*H₃)a), 46.1 (3-C), 68.8 (4&5-C), 73.3 (PhCH₂), 82.4 (2-C), 105.6 (1-C), 111.2 (*C*(CH₃)₂) 127.8, 127.9, 128.6, 138.1 (*Ph*CH₂). MS (ESI-TOF) m/z: [M + K]⁺ Calcd for C₁₅H₂₀O₄K 303.0999; Found 303.1078.

1,2-Di-*O*-acetyl-3-deoxy-5-(*O*-benzyl)-α/β-D-apio-D-furanose (28): Following the procedure described for the synthesis of **19**, compound **27** (1.3 g, 4.92 mmol) rendered **28** (1.2 g, 79%) as a colorless oil. Mixture of α +β (2:1). ¹H NMR (300 MHz, CDCl₃) δ ppm 2.00 (s, major, C(CH₃)₂) 2.04 (s, minor, C(CH₃)₂) 2.07 (s, minor, C(CH₃)₂) 2.08 (s, major, C(CH₃)₂), 2.56 - 2.69 (m, major, 3-H) 2.69 - 2.83 (m, minor, 3-H) 3.46 - 3.74 (m, major & minor, 5-H) 3.80 - 3.94 (m, major & minor, 4-H) 4.20 - 4.34 (m, major & minor, 4-H) 4.51 (s, minor, PhCH₂), 4.54 (s, major, PhCH₂), 5.05 (t, *J* = 4.1 Hz, minor, 2-H), 5.08 (d, *J* = 2.6 Hz, major, 2-H), 6.13 (s, major, 1-H), 6.33 (d, *J* = 4.4 Hz, minor, 1-H), 7.27 - 7.40 (m, major & minor, *Ph*CH₂). HRMS (ESI-TOF) m/z: [M + K]⁺ Calcd for C₁₆H₂₀O₆K 347.0897; Found 347.0898.

General condition for Vorbrüggen coupling reaction: All operations were carried out under an argon protected atmosphere.

Silylation of nucleobases: The nucleobase (N^6 -Benzoyl protected in case of adenine) (2 eq.) was suspended in hexamethyldisilazane (50 eq.) containing trimethylsilyl chloride (0.7 eq.) and pyridine (10 eq.). The mixture was heated at reflux overnight. After cooling, the solvent was evaporated and dried under high vacuum.

Coupling at ambient condition (A): To the silvlated nucleobase was added compound 17/19/20/24 or 28 (1 eq.) dissolved in dry 1,2-dichloroethane (7 mL/mmol), and trimethylsilyl triflate or anhydrous SnCl₄ (2.5 eq.) was added dropwise at room temperature. The clear solution was stirred at rt.

Coupling under microwave condition (**B**): To the silvlated nucleobase was added compound **17/19/20/24** or **28** (1 eq.) dissolved in dry acetonitrile (7 mL/mmol), followed by the addition of trimethylsilyl triflate (0.2 eq.) at rt. The clear solution was irradiated to

microwave (continuous power-300W, preheating 0 °C \rightarrow 150 °C in 3 min, at 150 ± 3 °C for 5 min).

Workup procedure: The reaction mixture was quenched with saturated aqueous NaHCO₃ and extracted with ethyl acetate (3 times). The combined organic layers were dried over anhydrous Na₂SO₄ and evaporated. Purification of the residue by silica-gel flash column chromatography (MeOH-CH₂Cl₂) afforded the pure coupled product as white foam.

1'-(Thymin-1-vl)-2'-O-acetyl-3'-deoxy-5'-O-benzyl-α-D-apio-L-furanose (29): Using condition A, compound 19 (320 mg, 1.04 mmol) gave compound 29 (420 mg) in quantitative yield as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.84 (d, J = 0.9 Hz, 3H, 5-CH₃), 1.98 (s, 3H, 2'-OAc), 2.67 - 2.85 (m, 1H, 3'-H), 3.39 (dd, J = 9.1, 7.62 Hz, 1H, 5'-H), 3.57 (dd, J = 9.2, 6.0 Hz, 1H, 5'-H), 3.89 (t, J = 8.9 Hz, 1H, 4'-H), 4.36 (t, J = 8.1 Hz, 1H, 4'-H),4.43 (s, 2H, CH₂Ph), 5.39 (dd, J = 6.2, 2.3 Hz, 1H, 2'-H), 5.74 (d, J = 2.3 Hz, 1H, 1'-H), 6.89 - 7.02 (d, J = 0.9 Hz, 1H, 6-H), 7.21 - 7.38 (m, 5H, CH₂Ph), 8.85 (br s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.6 (5-CH₃), 20.6 (2'-OCOCH₃), 41.0 (3'-C), 66.3 (5'-C), 71.9 (4'-C), 73.5 (CH₂Ph), 91.2 (1'-C), 111.0 (5-C), 127.7 (CH₂Ph), 127.9 (CH₂Ph), 128.5 (CH₂Ph), 135.1 (6-C), 137.6 (CH₂Ph), 150.0 (2-C), 163.7 (4-C), 169.7 (2'-OCOCH₃). HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for C₁₉H₂₃N₂O₆ 375.1556; Found 375.1556.

1'-(N^6 -Benzoyladenin-9-yl)-2'-*O*-acetyl-3'-deoxy-5'-*O*-benzyl-α-D-apio-L-furanose (30): Using condition B, compound 20 (1.0 g, 3.56 mmol) gave compound 30 (1.0 g, 60%) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.00 (s, 3H, 2'-OAc), 3.11 - 3.25 (m, 1H, 3'-H), 3.49 (dd, *J* = 9.2, 7.2 Hz, 1H, 5'-H), 3.63 (dd, *J* = 9.4, 6.4 Hz, 1H, 5'-H), 4.00 (t, *J* = 8.5 Hz, 1H, 4'-H), 4.45 (s, 2H, PhC H_2), 4.50 (t, J = 8.1 Hz, 1H, 4'-H), 5.79 (dd, J = 5.9, 2.1 Hz, 1H, 2'-H), 6.04 (d, J = 2.3 Hz, 1H, 1'-H), 7.21 - 7.32 (m, 5H, CH₂Ph), 7.37 - 7.47 (m, 2H, H_m) Bz), 7.47 - 7.56 (m, 1H, H_p Bz), 7.90 - 7.97 (m, 2H, H_p Bz), 7.98 (s, 1H, 8-H), 8.72 (s, 1H, 2H), 9.11 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 20.6 (2'-OCOCH₃), 41.0 (3'-C), 66.2 (5'-C), 72.1 (4'-C), 73.4 (CH₂Ph), 77.0 (2'-C), 90.2 (1'- C), 123.6 (5-C), 127.7 (C_o, C_p Bn), 127.8 (C_o Bz), 128.4 (C_m Bn), 128.8 (C_m Bz), 132.7 (C_p Bz), 133.6 (C_{ipso} Bz), 137.6 (C_{ipso} Bn), 141.3 (8-C), 149.5 (6-C), 151.2 (4-C), 152.8 (2-C), 164.6 (N⁶Bz-CO), 169.9 (2'-OCOCH₃). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₆H₂₆N₅O₅ 488.1934; Found 488.1937.

Spectral data for compound **1'**-(*N*⁶-**Benzoyladenin-1-yl)-3'-deoxy-5'-***O***-benzyl-***a***-D**-apio-Lfuranose (**31**): ¹H NMR (300 MHz, CDCl₃) δ ppm 2.45 - 2.61 (m, 1H, 3'-H), 3.68 (dd, *J* = 9.4, 6.4 Hz, 1H, 5'-H), 3.76 (dd, *J* = 9.5, 6.3 Hz, 1H, 5'-H), 4.22 (t, *J* = 8.8 Hz, 1H, 4'-H), 4.41 (t, *J* = 8.2 Hz, 1H, 4'-H), 4.45 - 4.52 (m, 2H, CH₂Ph), 4.62 (d, *J* = 5.0 Hz, 1H, 2'-H), 6.56 (s, 1H, 1'-H), 7.19 - 7.28 (m, 5H, CH₂Ph), 7.29 - 7.37 (m, 2H, H_mBz), 7.39 - 7.47 (m, 1H, H_p Bz), 7.97 (s, 1H, 8-H), 8.16 - 8.22 (m, 2H, H_o Bz), 8.40 (s, 1H, 2-H), 12.45 (br s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 41.2 (3'-C), 65.9 (5'-C), 72.1 (4'-C), 73.6 (CH₂Ph), 77.6 (2'-C), 96.6 (1'-C), 114.7 (5-C), 127.9 (C_o Bn), 128.2 (C_p Bn), 128.5 (C_m Bz), 128.8 (C_m Bn), 129.9 (C_o Bz), 132.4 (C_p Bz), 137.5 (C_{ipso} Bz), 137.8 (C_{ipso} Bn), 142.0 (8-C), 142.2 (2-C), 148.8 (6-C), 158.0 (4-C), 175.5 (Bz CO). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₄H₂₄N₅O₄ 446.1828; Found 446.1839.

1'-(Thymin-1-yl)-3'-deoxy-β-D-apio-L-furanose (**33**): Spectral data for the compound mixture **33** (minor) + **5a**: ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.77 (d, *J* = 0.9 Hz, 1.06H, minor 5-CH₃), 1.80 (d, *J* = 1.2 Hz, 2.89H, 5-CH₃, major), 2.22 - 2.36 (m, 1H, 3'-H, major), 2.52-2.60 (m, 0.29H, 3'-H, minor) 3.40 - 3.52 (m, 1.43H, 5'-H, major & minor), 3.62 - 3.72 (m, 1.43H, 5'-H, major & minor), 3.73 - 3.81 (m, 1.11H, 4'-H, major), 3.81-3.87 (m, 0.31H, 4'-H, minor), 9.95-4.02 (t, *J* =7.9 Hz, 0.39H, 4'-H, minor), 4.11-4.16 (m, 0.36H, 2'-H, minor), 4.19 (td, *J* = 5.1, 2.1 Hz, 1.05H, 2'-H, major), 4.33 (t, *J* = 7.9 Hz, 1H, 4'-H, major),

4.51 (t, J = 5.1 Hz, 1.34H, 5'-OH, major & minor), 5.29 (d, J = 4.7 Hz, 0.37H, 2'-OH, minor), 5.51 (d, J = 5.0 Hz, 1.02H, 2'-OH, major), 5.61 (d, J = 2.1 Hz, 1H, 1'-H, major), 5.88 (d, J = 3.2 Hz, 0.36H, 1'-H, minor), 7.30 (d, J = 1.2 Hz, 0.36H, 6-H, minor), 7.38 (d, J = 1.2 Hz, 1.02H, 6-H, major), 11.21 (s, 0.39H, NH, minor), 11.27 (s, 1.01H, major). ¹³C NMR (75 MHz, DMSO-d₆) δ ppm 12.1 (5-CH₃, major), 12.2 (5-CH₃, minor), 43.6 (3'-C, major), 46.1 (3'-C, minor), 57.6 (5'-C, major), 57.7 (5'-C, minor), 69.3 (2'-C, minor), 69.8 (4'-C, minor), 71.2 (4'-C, major), 74.2 (2'-C, major), 87.9 (1'-C, minor), 92.2 (1'-C, major), 106.8 (5-C, minor), 108.9 (5-C, major), 135.7 (6-C, major), 138.0 (6-C, minor), 150.3 (2-C, major), 150.4 (2-C, minor), 163.9 (4-C, major), 164.1 (4-C, minor).

1'-(Thymin-1-yl)-2',3'-di(O-acetyl)-5'-O-benzyl-α-D-apio-L-furanose (34): Using condition – A, compound 24 (100 mg, 0.27 mmol) gave compound 34 (100 mg, 85%) as a colorless glass . ¹H NMR (300 MHz, CDCl₃) δ ppm 1.95 (d, J = 1.2 Hz, 3H, 5-CH₃), 2.04 (s, 3H, Ac), 2.08 (s, 3H, Ac), 3.88 (s, 2H, 5'-H), 4.20 (d, J = 10.5 Hz, 1H, 4'-H), 4.55 (s, 2H, CH_2Ph), 4.56 (d, J = 10.5 Hz, 1H, 4'-H), 5.63 (d, J = 5.0 Hz, 1H, 2'-H), 5.96 (d, J = 5.0 Hz, 1H, 1'-H), 7.28 (d, J = 1.2 Hz , 1H, 6-H), 7.30 - 7.41 (m, 5H, CH₂Ph), 8.52 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.7 (5-CH₃), 20.5 (Ac-CH₃), 21.6 (Ac-CH₃), 66.7 (5'-C), 73.2 (4'-C), 73.8 (CH₂Ph), 78.1 (2'-C), 86.2 (3'-C), 88.2 (1'-C), 111.4 (5-C), 127.8 (C₀ Bn), 128.0 (Cp Bn), 128.5 (Cm Bn), 135.0 (6-C), 137.3 (Cipso Bn), 150.2 (2-C), 163.3 (4-C), 169.1 (Ac-CO), 169.9 (Ac-CO). HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for $C_{21}H_{25}N_2O_8$ 433.1605; Found 431.1603.

1'- $(N^6$ -Benzovladenin-9-vl)-2',3'-di(*O*-acetvl)-5'-*O*-benzvl- α -D-apio-L-furanose (35): Using condition- B, compound 24 (220 mg, 0.6 mmol) gave compound 35 (130 mg, 40%) and **36** (20 mg, 6%). ¹H NMR (300 MHz, CDCl₃) δ ppm 2.04 (s, 3H, Ac), 2.07 (s, 3H, Ac), 3.94 - 4.04 (2d, J = 10.0 Hz, 2H, 5'-H), 4.37 (d, J = 10.5 Hz, 1H, 4'-H), 4.59 (s, 2H, CH₂Ph),

4.71 (d, *J* = 10.5 Hz, 1H, 4'-H), 6.13 (d, *J* = 4.4 Hz, 1H, 2'-H), 6.17 (d, *J* = 4.1 Hz, 1H, 1'-H), 7.31 - 7.39 (m, 5H, CH₂Ph), 7.51 - 7.56 (m, 2H, H_m Bz), 7.58 - 7.62 (m, 1H, H_p Bz), 8.00 -8.05 (m, 2H, H_o Bz) 8.23 (s, 1H, 8-H), 8.82 (s, 1H, 2-H), 9.01 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 20.5 (Ac- CH₃), 21.5 (Ac-CH₃), 66.3 (5'-C) 73.8 (CH₂Ph & 4'-C), 78.7 (2'-C), 86.4 (3'-C), 87.9 (1'-C), 123.1 (5-C), 127.8 (C_o Bn) 127.8 (C_o Bz), 128.1 (Cp Bn), 128.5 (C_m Bn), 128.9 (C_m Bz), 132.8 (C_m Bz), 133.6 (C_{ipso} Bn), 137.3 (C_{ipso} Bz), 141.1 (8-C), 149.5 (4-C), 151.8 (6-C), 152.9 (2-C), 164.5 (N⁶COPh), 168.9 (COCH₃), 169.9 (COCH₃). HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for C₂₈H₂₈N₅O₇ 546.1989; Found 546.2000. Spectral data for compound 1'-(N⁶-Benzoyladenin-9-yl)-2'-(O-trimethylsilyl)-3'-(O-acetyl)-5'-Obenzyl-α-D-apio-L-furanose (36): ¹H NMR (300 MHz, CDCl₃) δ ppm 0.14 (s, 9H, 2'-OSi(CH₃)₃) 1.89 (s, 3H, 3'-Ac) 3.96 (d, *J* = 10.0 Hz, 1H, 5'-H) 4.05 (d, *J* = 9.7 Hz, 1H, 5'-H) 4.34 (d, J = 10.5 Hz, 1H, 4'-H) 4.49 (d, J = 11.7 Hz, 1H, CH_2Ph) 4.57 (d, J = 12.0 Hz, 1H, CH_2Ph) 4.71 (d, J = 10.5 Hz, 1H, 4'-H) 5.05 (d, J = 2.6 Hz, 1H, 2'-H) 6.04 (d, J = 2.6 Hz, 1H, 1'-H) 7.27 - 7.39 (m, 5H, CH₂Ph) 7.50 - 7.56 (m, 2H, H_m Bz) 7.57 - 7.62 (m, 1H, H_p Bz) 8.00 - 8.06 (m, 2H, Ho Bz) 8.15 (s, 1H, 8-H) 8.81 (s, 1H, 2-H) 9.08 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -0.1 (SiCH₃), 21.6 (Ac-CH₃), 66.0 (5'-C), 73.7 (CH₂Ph), 74.4 (4'-C), 79.0 (2'-C), 88.1 (3'-C), 91.7 (1'-C), 123.4 (5-C), 127.7 (C_p Bn), 127.85 (C_p Bz), 127.86 (Co Bn), 128.4 (Cm Bn), 128.9 (Cm Bz), 132.8 (Cp Bz), 133.7 (Cipso Bn), 137.6 (Cipso Bz), 141.3 (8-C), 149.4 (4-C), 151.3 (6-C), 152.7 (2-C), 164.6 (N⁶Bz-CO), 170.0 (Ac-CO). HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for C₂₉H₃₄N₅O₆Si 576.2278; Found 576.2291.

1'-(Thymin-1-yl)-3'-deoxy-5'-O-benzyl- α -D-apio-L-furanose (37): Acetyl protected compound 29 (400 mg, 1.07 mmol) was dissolved in 7N ammonia in MeOH (15 mL). The mixture was stirred at room temperature until completion (for about 3-5h) as indicated by TLC. Solvent was evaporated and the residue was purified by flash column chromatography using 0.5-1 % MeOH-CH₂Cl₂ to afford the title compound **37** (341 mg, 96%) as a white

foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.83 (d, J = 1.2 Hz, 3H, 5-CH₃), 2.27 - 2.49 (m, 1H, 3'-H), 3.57 (dd, J = 9.2, 7.8 Hz, 1H, 5'-H), 3.78 (dd, J = 9.2, 6.0 Hz, 1H, 5'-H), 4.03 (dd, J = 10.5, 8.5 Hz, 1H, 4'-H), 4.29 - 4.38 (m, 2H, 4'-H & 2'-H), 4.45 (s, 2H, CH₂Ph), 5.02 (br s, 1H, 2'-OH), 5.67 (s, 1H, 1'-H), 7.11 (d, J = 1.2 Hz, 1H, 6-H), 7.19 - 7.30 (m, 5H, CH₂Ph), 10.44 (br s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.6 (5-CH₃), 41.3 (3'- C), 66.6 (5'-C), 72.9 (4'-C), 73.6 (CH₂Ph), 75.8 (2'-C), 94.3 (1'-C), 110.5 (5-C), 127.72 (CH₂Ph), 127.74 (CH₂Ph), 128.4 (CH₂Ph), 134.7 (6- C), 137.9 (CH₂Ph), 150.6 (2-C), 164.5 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₁N₂O₅ 333.1450; Found 333.1458.

1'-(Adenin-9-yl)-3'-deoxy-5'-*O***-benzyl-α-D-apio-L-furanose (38):** Compound **30** (1.0 g, 2.05 mmol) was dissolved in 7N ammonia in MeOH (30 mL). The mixture was stirred at room temperature for 48 h. Solvent was evaporated and the residue was purified by flash column chromatography using 2% MeOH-CH₂Cl₂ to afford the title compound **38** (650 mg, 75%) as a white foam [Procedure to remove acetamide residue if any: Suspend the product in water and then collect it by filtration]. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.75 - 2.89 (m, 1H, 3'-H), 3.53 (t, *J* = 8.8 Hz, 1H, 5'-H), 3.73 (dd, *J* = 9.4, 5.9 Hz, 1H, 5'-H), 3.86 (t, *J* = 8.2 Hz, 1H, 4'-H), 4.40 (t, *J* = 7.8 Hz, 1H, 4'-H), 4.45 - 4.56 (m, 2H, Bn H), 4.63 (td, *J* = 5.3, 2.1 Hz, 1H, 2'-H), 5.76 (d, *J* = 4.7 Hz, 1H, 2'-OH), 5.90 (d, *J* = 2.3 Hz, 1H, 1'-H), 7.26 (br s, 2H, NH), 7.27 - 7.39 (m, 5H, CH₂*Ph*), 8.15 (s, 1H, 2-H), 8.23 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 41.7 (3'-C), 66.8 (5'-C), 71.1 (4'-C), 72.3 (Bn C), 74.4 (2'-C), 91.1 (1'-C), 148.8 (4-C), 152.5 (2-C), 156.0 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₀N₅O₃ 342.1566; Found 342.1565.

1'-(Thymin-1-yl)-5'-*O***-benzyl-α-D-apio-L-furanose** (**39**): Following a similar procedure described for compound **37**, compound **34** (100 mg, 0.23 mmol) gave compound **39** (81 mg,

86 %) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.81 (d, J = 0.9 Hz, 3H, 5-CH₃), 3.60 (d, J = 9.7 Hz, 1H, 4'-H), 3.85 (d, J = 9.7 Hz, 1H, 4'-H), 3.90 (d, J = 1.2 Hz, 1H, 3'-OH), 4.06 (dd, J = 9.4, 1.5 Hz, 1H, 5'-H), 4.17 (d, J = 9.4 Hz, 1H, 5'-H), 4.41 (d, J = 3.5 Hz, 1H, 2'-H), 4.50 - 4.69 (app-q, J = 12.0 Hz, 2H, CH₂Ph), 5.25 (d, J = 3.5 Hz, 1H, 2'-OH), 5.72 (s, 1H, 1'-H), 7.23 - 7.37 (m, 5H, CH₂Ph), 7.52 (d, J = 1.2 Hz, 1H, 6-H), 10.81 (br s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.4 (5-CH₃), 69.6 (4'-C), 73.7 (CH₂Ph), 77.0 (5'-C), 80.0 (2'-C), 80.5 (3'-C), 94.4 (1'-C), 108.6 (5-C), 127.77 (C_o Bn), 127.84 (C_p Bn), 128.4 (C_m Bn), 137.55 (C_{ipso} Bn), 137.62 (6-C) 151.3 (2-C), 164.8 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₁N₂O₆ 349.1400; Found 349.1384.

1'-(Adenin-9-yl)-5'-*O***-benzyl-***a***-D-apio-L-furanose (40):** Following a similar procedure described for compound **38**, compound **35** (120 mg, 0.22 mmol) gave compound **40** (73 mg, 93%) as a white foam. The same procedure was employed to convert **36** to **40**. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.57 - 3.70 (2d, *J* = 9.7 Hz, 2H, 5'-H), 4.00 (d, *J* = 8.8 Hz, 1H, 4'-H), 4.11 (d, *J* = 9.1 Hz, 1 H4'-H), 4.39 (dd, *J* = 5.3, 2.9 Hz, 1H, 2'-H) 4.51 - 4.64 (2d, *J* = 12.3 Hz, 2H, CH₂Ph), 5.59 (s, 1H, 3'-OH), 5.90 (d, *J* = 2.9 Hz, 1H, 1'-H), 5.97 (d, *J* = 5.6 Hz, 1H, 2'-OH), 7.27 (s, 2H, NH), 7.28 - 7.43 (m, 5H, CH₂Ph) 8.15 (s, 1H, 2-H), 8.29 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 71.1 (5'-C), 72.7 (CH₂Ph), 75.6 (4'-C), 79.8 (3'-C), 80.3 (2'-C), 90.7 (1'-C), 118.8 (5-C), 127.3 (C_p Bn), 127.4 (C_o Bn), 128.2 (C_m Bn), 138.5 (C_{*ipso*} Bn), 139.7 (8-C), 149.0 (4-C), 152.5 (2-C), 156.0 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₀N₅O₄ 358.1515; Found 358.1512.

1'-(Thymin-1-yl)-3'-deoxy-\alpha-D-apio-L-furanose (5a)^[11]: Compound 37 (300 mg, 0.9 mmol) was dissolved in MeOH (10 mL), to this was added Pd-C (300 mg, 10% Pd, wet ~50%). A stream of hydrogen gas was bubbled through the reaction mixture with vigorous stirring for about 1 h and the mixture was then stirred under hydrogen atmosphere overnight

Page 37 of 61

The Journal of Organic Chemistry

at room temperature. The catalyst was filtered off, the filtrate was concentrated and purified by silica-gel flash column chromatography eluting with 6-8% MeOH-CH₂Cl₂ to afford compound **5a** (190 mg, 86%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.79 (d, *J* = 1.2 Hz, 3H, 5-CH₃), 2.22 - 2.36 (m, 1H, 3'-H), 3.46 (ddd, *J* = 10.8, 7.7, 5.3 Hz, 1H, 5'-H), 3.62 - 3.71 (m, 1H, 5'-H), 3.76 (t, *J* = 8.6 Hz, 1H, 4'-H), 4.18 (td, *J* = 5.0, 2.1 Hz, 1H, 2'-H), 4.33 (t, *J* = 7.8 Hz, 1H, 4'-H), 4.51 (t, *J* = 5.1 Hz, 1H, 5'-OH), 5.51 (d, *J* = 4.7 Hz, 1H, 2'-OH), 5.61 (d, *J* = 2.1 Hz, 1H, 1'-H), 7.38 (d, *J* = 1.2 Hz, 1H, 6-H), 11.27 (br s, 1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 12.1 (5-CH₃), 43.6 (3'-C), 57.6 (5'-C), 71.1 (4'-C), 74.2 (2'-C), 92.2 (1'-C), 108.9 (5-C), 135.7 (6-C), 150.3 (2-C), 163.9 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₅N₂O₅ 243.0981; Found 243.0990.

1'-(Adenin-9-yl)-3'-deoxy-α-D-apio-L-furanose (5b): Compound **38** (450 mg, 1.32 mmol) was dissolved in 1:1 v/v mixture of MeOH-formic acid (40 mL), to this was added Pd(OH)₂-C (300 mg, 10% Pd, wet ~50%) and stirred at 55 °C for 5-8h . The catalyst was filtered off and the filtrate was concentrated. The residue contained compound **5b** and **41** as a mixture. The residue was dissolved in 7N NH₃-MeOH and stirred at room temperature for 3h. The volatiles were evaporated and the residue purified by silica-gel flash column chromatography eluting with 10-12% MeOH-CH₂Cl₂ to afford compound **5b** (265 mg, 80%) as a white solid. Spectral data for **1'-(adenin-9-yl)-3'-deoxy-5'-O-formyl-α-D-apio-L-furanose (41):** ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.82 - 3.00 (m, 1H, 3'-H), 3.86 (t, *J* = 8.2 Hz, 1H, 4'-H), 4.21 (dd, *J* = 11.0, 7.8 Hz, 1H, 5'-H), 4.32 - 4.46 (m, 2H, 4' & 5'-H's), 4.70 (br s, 1H, 2'-H), 5.93 (d, *J* = 2.1 Hz, 1H, 1'-H), 7.28 (s, 2H, NH), 8.15 (s, 1H, 2-H), 8.24 (s, 1H, 5'-OCOH), 8.25 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 41.3 (3'-C), 61.3 (5'-C), 71.1 (4'-C), 74.7 (2'-C), 91.8 (1'-C), 119.7 (5-C), 139.9 (8-C), 149.4 (4-C), 153.3 (2-C), 156.5 (6-C), 162.8 (5'-OCOH). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₁H₁₄N₅O₄ 280.1046; Found 280.1046. Spectral data for **1-(adenin-9-yl)-3'-deoxy-α-D-apio-L-furanose (5b):** ¹H NMR (300 MHz, DMSO- d_6) δ ppm 2.53 - 2.66 (m, 1H, 3'-H), 3.52 (t, J = 8.8 Hz, 1H, 5'-H), 3.67 - 3.77 (m, 1H, 5'-H), 3.86 (t, J = 8.2 Hz, 1H, 4'-H), 4.35 (t, J = 7.8 Hz, 1H, 4'-H), 4.54 (br s, 1H, 5'-OH), 4.63 (br s, 1H, 2'-H), 5.64 (d, J = 4.7 Hz, 1H, 2'-OH), 5.89 (d, J = 2.3 Hz, 1H, 1'-H), 7.25 (br s, 2H, NH₂), 8.15 (s, 1H, 2-H), 8.22 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO- d_6) δ ppm 44.1 (3'-C), 57.6 (5'-C), 70.8 (4'-C), 74.4 (2'-C), 91.1 (1'-C), 119.2 (5- C), 138.9 (8-C), 148.8 (4-C), 152.5 (2-C), 156.0 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₄N₅O₃ 252.1097; Found 252.1090.

1'-(Thymin-1-yl)-α-D-apio-L-furanose (6a): Following a similar procedure described for compound **5a**, compound **39** (210 mg, 0.60 mmol) gave compound **6a** (110 mg, 71%) as a white foam. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.77 (d, *J* = 1.2 Hz, 3H, 5-CH₃), 3.54 (s, 2H, 5'-H), 3.88 (d, *J* = 9.1 Hz, 1H, 4'-H), 3.93 (br s, 1H, 2'-H), 3.98 (d, *J* = 9.1 Hz, 1 H), 4.57 (br s, 1H, 3'-OH), 5.04 (s, 1H, 5'-OH), 5.67 (d, *J* = 2.6 Hz, 1H, 1'-H), 5.72 (d, *J* = 4.7 Hz, 1H, 2'-OH), 7.62 (d, *J* = 1.2 Hz, 1H, 6-H), 11.25 (br s, 1H, NH).¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 13.0 (5-*C*H₃), 63.0 (5'-C), 76.5 (4'-C), 80.5 (2'-C), 81.0 (3'-C), 93.0 (1'-C), 108.7 (5-C), 137.9 (6-C), 151.2 (2-C), 164.6 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₅N₂O₆ 259.0930; Found 259.0927.

1'-(Adenin-9-yl)-α-D-apio-L-furanose (6b)^[46]: Compound **40** (20 mg, 0.056 mmol) was dissolved in 9:1 v/v mixture MeOH-formic acid (2 mL), to this was added Pd(OH)₂-C (20 mg, 10% Pd, wet ~50%) and stirred at 55 °C for 5-8h. The catalyst was filtered off, the filtrate was concentrated and the residue was purified by silica-gel flash column chromatography eluting with 10-14% MeOH-CH₂Cl₂ to afford compound **6b** (12 mg, 80%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.62 (d, J = 5.6 Hz, 2H, 5'-H), 3.98 (d, J = 9.1 Hz, 1H, 4'-H), 4.04 (d, J = 9.1 Hz, 1H, 4'-H), 4.38 (br s, 1H, 2'-H), 4.64 (t, J = 5.7 Hz, 1H, 5'-OH), 5.36 (s, 1H, 3'-OH), 5.85 (d, J = 4.7 Hz, 1H, 2'-OH), 5.90 (d, J = 2.9 Hz,

1H, 1'-H), 7.26 (s, 2H, NH), 8.15 (s, 1H, 2-H), 8.31 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO- d_6) δ ppm 62.0 (5'-C), 75.3 (4'-C), 80.1 (2'-C), 80.3 (3'-C), 90.6 (1'-C), 118.7 (5-C), 139.6 (8-C), 149.0 (4-C), 152.3 (2-C), 155.9 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₄N₅O₄ 268.1046; Found 268.1036.

1'-(Thymin-1-yl)-3'-deoxy-5'-*O*-benzyl-β-D-apio-D-furanose (42): Using Vorbrüggen coupling condition-A and then following procedure described for **37**, compound **28** (550 mg, 1.78 mmol) gave **42** (360 mg, 60%) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.84 (d, J = 0.7 Hz, 3H, 5-CH₃), 2.68 (ddt, J = 12.7, 7.7, 6.4 Hz, 1H, 3'-H), 3.51 (dd, J = 9.5, 6.6 Hz, 1H, 5'-H), 3.59 (dd, J = 9.5, 5.0 Hz, 1H, 5'-H), 4.01 (dd, J = 8.8, 7.9 Hz, 1H, 4'-H), 4.22 (dd, J = 6.2, 3.9 Hz, 1H, 2'-H), 4.32 (dd, J = 8.8, 7.8 Hz, 1H, 4'-H), 4.50 (s, 2H, PhCH₂), 5.60 (d, J = 3.8 Hz, 1H, 1'-H), 7.24 (d, J = 1.3 Hz, 1H, 6-H), 7.26 - 7.38 (m, 5H, *Ph*CH₂), 9.77 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.5 (5-CH₃), 46.4 (3'-C), 68.6 (5'-C), 71.4 (4'-C), 73.3 (PhCH₂), 79.2 (2'-C), 94.3 (1'-C), 110.4 (5-C), 127.7, 127.9, 128.5 (*Ph*CH₂) 135.0 (6-C) 137.8 (*Ph*CH₂), 151.6 (2-C), 164.1 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₁N₂O₅ 333.1450; Found 333.1452.

1'-(Adenin-9-yl)-3'-deoxy-5'-*O*-benzyl-β-D-apio-D-furanose (43): Using Vorbrüggen coupling condition-B and then following procedure described for **38**, compound **28** (1.55 g, 5 mmol) gave **43** (480 mg, 28%) and its α-anomer (200 mg, 11%) as a white solid. ¹H NMR (300 MHz, DMSO- d_6) δ ppm 2.60 (quind, J = 8.1, 5.0 Hz, 1H, 3'-H), 3.61 (t, J = 8.5 Hz, 1H, 5'-H), 3.70 (dd, J = 9.7, 5.0 Hz, 1H, 5'-H), 4.05 (t, J = 8.8 Hz, 1H, 4'-Hb), 4.17 (t, J = 8.2 Hz, 1H, 4'-Ha), 4.51 (s, 2H, PhC H_2), 4.70 (dt, J = 7.6, 5.7 Hz, 1H, 2'-H), 5.69 (d, J = 5.9 Hz, 1H, 2'-OH), 5.79 (d, J = 5.6 Hz, 1H, 1'-H), 7.26 (s, 2H, NH₂), 7.29 - 7.40 (m, 5H, *Ph*CH₂), 8.13 (s, 1H, 2-H), 8.31 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO- d_6) δ ppm 46.7 (3'-C), 69.2 (5'-C), 70.5 (4'-C), 72.2 (PhCH₂), 75.1 (2'-C), 90.0 (1'-C), 119.2 (5-C), 127.44, 127.46, 128.3,

138.3 (*Ph*CH₂), 139.8 (8-C), 149.4 (4-C), 152.6 (2-C), 156.0 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₀N₅O₃ 342.1566; Found 342.1553. Spectral data for **1'-(Adenin-9-yl)-3'-deoxy-5'-***O*-benzyl-α-D-apio-D-furanose. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.69 - 2.83 (m, 1H, 3'-H), 3.55 (dd, J = 9.5, 7.2 Hz, 1H, 5'-H), 3.66 (dd, J = 9.5, 5.1 Hz, 1H, 5'-H), 3.73 (dd, J = 8.5, 7.0 Hz, 1H, 4'-Hb), 4.29 (q, J = 5.6 Hz, 1H, 2'-H), 4.36 (t, J = 8.2 Hz, 1H, 4'-Ha), 4.54 (s, 2H, PhC*H*₂), 5.53 (d, J = 5.3 Hz, 1H, 2'-OH), 6.19 (d, J = 5.3 Hz, 1H, 1'-H), 7.22 (s, 2H, NH₂), 7.26 - 7.43 (m, 5H, *Ph*CH₂), 8.14 (s, 1H, 2-H), 8.16 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 45.3 (3'-C), 69.2 (4'-C), 69.4 (5'-C), 72.0 (2'-C) 72.2 (PhCH₂), 84.4 (1'-C), 118.2 (5-C), 127.48, 127.54, 128.3, 138.3 (*Ph*CH₂), 140.2 (8-C), 149.6 (4-C), 152.4 (2-C), 155.8 (6-C).

1'-(Thymin-1-yl)-5'-*O*-benzyl-β-D-apio-D-furanose (44): Using Vorbrüggen coupling condition-A and then following procedure described for **37**, compound **17** (500 mg, 1.36 mmol) rendered **44** (460 mg, 97%) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.89 (d, J = 1.2 Hz, 3H, 5-CH₃), 3.49 (d, J = 0.9 Hz, 1H, 3'-OH), 3.52 (s, 2H, 5'-H), 4.07 (d, J = 9.7 Hz, 1H, 4'-H_b), 4.24 (dd, J = 10.0, 0.9 Hz, 1H, 4'-H_a), 4.27 (dd, J = 5.6, 3.8 Hz, 1H, 2'-H), 4.38 (d, J = 4.1 Hz, 1H, 2'-OH), 4.56 (s, 2H, PhCH₂), 5.71 (d, J = 5.9 Hz, 1H, 1'-H), 7.22 (d, J = 1.2 Hz, 1H, 6-H), 7.27 - 7.40 (m, 5H, *Ph*CH₂), 9.18 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.5 (5-CH₃), 71.0 (5'-C), 73.7 (PhCH₂), 75.7 (4'-C), 76.9 (2'-C), 78.1 (3'-C), 92.4 (1'-C), 111.0 (5-C), 127.8, 128.0, 128.6, 137.4 (*Ph*CH₂), 135.5 (6-C), 151.5 (2-C), 163.7 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₁N₂O₆ 349.1400; Found 349.1414.

1'-(Adenin-9-yl)-5'-*O***-benzyl-β-D-apio-D-furanose** (**45**): Using Vorbrüggen coupling condition-B and then following procedure described for **38**, compound **17** (2.7 g, 7.37 mmol) rendered **45** (1.2 g, 46%) as a white foam. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.53 (q, J = 10.0 Hz, 2H, 5'-H), 3.83 (d, J = 9.1 Hz, 1H, 4'-H), 4.36 (d, J = 10.0 Hz, 1H, 4'-H), 4.58 (s,

2H, PhC*H*₂), 4.89 (t, J = 7.2 Hz, 1H, 2'-H), 5.08 (s, 1H, 3'-OH), 5.53 (d, J = 6.7 Hz, 1H, 2'-OH), 5.88 (d, J = 7.6 Hz, 1H, 1'-H), 7.19 - 7.29 (br.s, 2H, NH₂), 7.29 - 7.45 (m, 5H, *Ph*CH₂), 8.14 (s, 1H, 2-H), 8.34 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 71.3 (5'-C), 72.4 (PhCH₂), 73.8 (2'-C), 74.8 (4'-C), 77.5 (3'-C), 87.8 (1'-C), 119.4 (5-C), 127.3, 127.4, 128.2, 138.4 (*Ph*CH₂), 140.3 (8-C), 149.6 (4-C), 152.6 (2-C), 156.1 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₀N₅O₄ 358.1515; Found 358.1516.

1'-(Thymin-1-yl)-3'-deoxy-β-D-apio-D-furanose (2a)^[11]: Following the procedure described for the synthesis of **5a**, compound **42** (350 mg, 1.05 mmol) gave **2a** (220 mg, 86%) as a white solid. ¹H NMR (300 MHz, CD₃OD) δ ppm 1.89 (d, J = 1.2 Hz, 3H, 5-CH₃) 2.39 - 2.55 (m, 1H, 3'-H), 3.65 (dd, J = 10.8, 6.7 Hz, 1H, 5'-H), 3.73 (dd, J = 11.0, 4.8 Hz, 1H, 5'-H), 4.02 - 4.10 (t, J = 8.2 Hz, 1H, 4'-H), 4.17 - 4.26 (m, 2H, 2' & 4'-H's), 5.72 (d, J = 5.6 Hz, 1H, 1'-H), 7.46 (d, J = 1.2 Hz, 1H, 6-H). ¹³C NMR (75 MHz, CD₃OD) δ ppm 11.2 (5-CH₃), 48.3 (3'-C), 60.5 (5'-C), 70.3 (4'-C), 75.7 (2'-C), 92.3 (1'-C), 110.4 (5-C), 137.1 (6-C), 151.6 (2-C), 165.2 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₅N₂O₅ 243.0981; Found 243.0975.

1'-(Adenin-9-yl)-3'-deoxy-β-D-apio-D-furanose (2b)^[8]: Following the procedure described for the synthesis of **5b**, compound **43** (600 mg, 1.76 mmol) gave **2b** (390 mg, 88%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.34 - 2.48 (m, 1H, 3'-H), 3.56 (dd, J = 10.7, 7.8 Hz, 1H, 5'-H), 3.68 (dd, J = 10.7, 4.5 Hz, 1H, 5'-H), 4.04 (t, J = 8.8 Hz, 1H, 4'-H), 4.13 (t, J = 8.2 Hz, 1H, 4'-H), 4.62 (t, J = 6.4 Hz, 1H, 2'-H), 4.79 (br.s, 1H, 5'-OH), 5.61 (br.s, 1H, 2'-OH), 5.79 (d, J = 5.6 Hz, 1H, 1'-H), 7.26 (s, 2H, NH₂), 8.15 (s, 1H, 2-H), 8.31 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 49.0 (3'-C), 60.2 (5'-C), 70.3 (4'-C), 75.1 (2'-C), 90.0 (1'-C), 119.2 (5-C), 139.6 (8-C), 149.5 (4-C), 152.6 (2-C), 156.0 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₄N₅O₃ 252.1097; Found 252.1081.

1'-(Adenin-9-yl)-β-D-apio-D-furanose (3b)^[46]: Following the procedure described for the synthesis of **6b**, compound **45** (1.2g, 3.37 mmol) rendered title compound **3b** (800 mg, 89%) as a white solid. ¹H NMR (300 MHz, DMSO- d_6) δ ppm 3.46 (q, *J* = 11.1 Hz, 1H, 5'-H), 3.76 (d, *J* = 9.1 Hz, 1H, 4'-H), 4.31 (d, *J* = 9.4 Hz, 1H, 4'-H), 4.80 (t, *J* = 6.4 Hz, 1H, 2'-H), 4.85 (s, 1H, 3'-OH), 4.91 (br.s, 1H, 5'-OH), 5.42 (d, *J* = 6.4 Hz, 1H, 2'-OH), 5.88 (d, *J* = 7.6 Hz, 1H, 1'-H), 7.26 (s, 2H, NH₂), 8.15 (s, 1H, 2-H), 8.33 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO- d_6) δ ppm 62.4 (5'-C), 73.4 (2'-C), 74.5 (4'-C), 78.2 (3'-C), 87.7 (1'-C), 119.3 (5-C), 139.9 (8-C), 149.7 (4-C), 152.6 (2-C), 156.0 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₄N₅O₄ 268.1046; Found 268.1066.

1'-(Thymin-1-yl)-2',3'-(*O***-thiocarbonyl)-5'-(***O***-benzyl)-β-D-apio-D-furanose** (**46**): To a solution of **44** (200 mg, 0.57 mmol) in DMF (4 mL) was added thiocarbonyldiimidazole (112 mg, 0.63 mmol) and the mixture was heated to 80 °C for 90 minutes. The volatiles were removed under reduced pressure and the residue was purified by silica-gel column chromatography (2% MeOH in CH₂Cl₂) to afford the title thiocarbonate **46** (200 mg, 89%) as a pale yellow solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.94 (d, J = 1.2 Hz, 3H, 5-CH₃), 3.89 (d, J = 11.1 Hz, 1H, 5'-H), 4.17 (d, J = 10.8 Hz, 1H, 5'-H), 4.30 - 4.42 (m, 2H, 4'-H), 4.57 - 4.71 (m, 2H, PhCH₂), 5.47 (d, J = 0.9 Hz, 1H, 1'-H), 5.82 (d, J = 1.2 Hz, 1H, 2'-H), 7.03 (d, J = 1.2 Hz, 1H, 6-H), 7.27 - 7.38 (m, 5H, *Ph*CH₂), 9.35 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.3 (5-CH₃), 67.7 (5'-C), 73.7 (PhCH₂), 77.4 (4'-C), 88.7 (2'-C), 97.5 (1'-C), 100.2 (3'-C), 112.2 (5-C), 127.6, 128.0, 128.5, 137.1 (*Ph*CH₂), 139.4 (6-C), 151.2 (2-C), 163.6 (4-C), 189.4 (CS). MS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₈H₁₉N₂O₆S 391.0964; Found 391.0958.

1'-(Adenin-9-yl)-2',3'-(O-thiocarbonyl)-5'-(O-benzyl)-β-D-apio-D-furanose (47): Following the procedure described for the synthesis of 46, compound 45 (300 mg, 0.84 mmol)

rendered title compound **47** (260 mg, 78%) as a pale yellow solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 4.03 (d, *J* = 10.8 Hz, 1H, 5'-H), 4.33 (d, *J* = 11.1 Hz, 1H, 4'-H), 4.42 (d, *J* = 11.1 Hz, 1H, 4'-H), 4.45 (d, *J* = 10.5 Hz, 1H, 5'-H), 4.61, 4.75 (d, *J* = 12.3 Hz, 2H, PhC*H*₂), 5.74 (br.s, 2H, NH₂), 6.14 (s, 1H, 2'-H), 6.20 (s, 1H, 1'-H), 7.29 - 7.40 (m, 5H, *Ph*CH₂), 7.87 (s, 1H, 8-H) 7.95 (s, 1H, 2-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm 67.0 (5'-C), 73.9 (PhCH₂), 75.0 (4'-C), 88.3 (2'-C), 90.3 (1'-C), 99.6 (3'-C), 119.9 (5-C), 128.0, 128.2, 128.6, 136.9 (*Ph*CH₂), 140.3 (8-C), 149.1 (4-C), 153.0 (2-C), 155.6 (6-C), 189.4 (CS). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₈H₁₈N₅O₄S 400.1079; Found 400.1060.

1'-(Thymin-1-yl)-2',3'-(dideoxydidehydro)-5'-(*O***-benzyl)-β-D-apio-D-furanose** (**48**): A solution of compound **46** (180 mg, 0.46 mmol) in trimethyphosphite (P(OCH₃)₃, 8.0 mL) was heated to 120 °C for 6h. The volatile materials were removed under reduced pressure and then co-evoporated 2-3 times with toluene. The residue was purified by silica-gel column chromatography (0-2% MeOH in CH₂Cl₂) to afford **48** (130 mg, 90%) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.91 (d, J = 1.2 Hz, 3H, 5-CH₃), 4.25 (s, 2H, 5'-H), 4.58 (s, 2H, PhCH₂), 4.63 - 4.74 (m, 1H, 4'-H), 4.77 - 4.90 (m, 1H, 4'-H), 5.67 - 5.76 (m, 1H, 2'-H) 6.91 (q, J = 1.2 Hz, 1H, 6-H), 7.00 (m, 1H, 1'-H), 7.29 - 7.44 (m, 5H, *Ph*CH₂), 8.47 (br.s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.6 (5-CH₃), 65.1 (5'-CH₂), 73.2 (PhCH₂), 75.6 (4'-C), 90.9 (1'-C), 111.3 (5-C), 119.9 (2'-C), 127.8, 128.1, 128.6, 137.3 (*Ph*CH₂), 135.3 (6-C), 145.4 (3'-C), 150.5 (2-C), 163.6 (4-C). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₈H₁₉N₂O₆S 337.1164; Found 337.1168.

1'-(Thymin-1-yl)-2',3'-(dideoxydihydro)- β/α -D-apio-D/L-furanose (1a + 4a): Following the procedure described for the synthesis of 25, compound 48 (120 mg, 0.38 mmol) rendered 1a and 4a as inseparable mixtures in 4: 1 ratio respectively (77 mg, 89%) as a white solid.

1'-(Thymin-1-yl)-3'-deoxy-5'-O-(tert-butyldimethylsilyl)- α -D-apio-L-furanose (49): Compound 5a (150 mg, 0.62 mmol) was dissolved in DMF (3.5 mL), to this was added imidazole (85 mg, 1.24 mmol) followed by tert-butyldimethylsilylchloride (TBSCl, 112 mg, 0.74 mmol). The mixture was stirred at room temperature for 18h. DMF was evaporated under reduced pressure. The residue was partitioned between EtOAc and brine. Organic layer separated, dried over sodium sulphate, solvent evaporated and the residue purified by silicagel flash column chromatography using 1-2% MeOH-CH₂Cl₂ to afford compound 49 (210 mg, 95%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.07 (2s, 6H, Si(CH₃)₂), 0.89 (S, 9H, C(CH₃)₃), 1.94 (d, *J* = 0.9 Hz, 3H, 5-CH₃), 2.32-2.46 (m, 1H, 3'-H), 3.84 (d, *J* = 10.3, 7.3 Hz, 1H, 5'-H), 3.97 (d, J = 10.3, 5.9 Hz, 1H, 5'-H), 4.10 (t, J = 8.5 Hz, 1H, 4'-H), 4.35 (t, J = 7.9 Hz, 1H, 4'-H), 4.39 (t, J = 4.1 Hz, 1H, 2'-H), 4.81 (d, J = 3.2 Hz, 1H, 2'-OH), 5.74 (s, 1H, 1'-H), 7.22 (d, J = 1.2 Hz, 1H, 6-H), 10.19 (br s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.51 (Si(CH₃)₂), -5.47 (Si(CH₃)₂), 12.7 (5-CH₃), 18.2 (C(CH₃)₃), 25.9 (C(CH₃)₃), 43.5 (3'-C), 59.8 (5'-C), 72.5 (4'-C), 76.1 (2'-C), 94.6 (1'-C), 110.5 (5-C), 134.8 (6-C), 150.7 (2-C), 164.4 (4-C). HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for C₁₆H₂₉N₂O₅Si 357.1846; Found 357.1852.

1'-(Adenin-9-yl)-3'-deoxy-5'-*O*-(*tert*-butyldimethylsilyl)-α-D-apio-L-furanose (50): Following a similar procedure described for compound **49**, compound **5b** (260 mg, 1.03 mmol) afforded compound **50** (310 mg, 82%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.10 (s, 3H, SiCH₃), 0.10 (s, 3H, SiCH₃), 0.91 (s, 9H, C(CH₃)₃), 2.65 - 2.78 (m, 1H, 3'-H), 3.97 (dd, J = 6.0, 1.3 Hz, 2H, 5'-H), 4.21 (dd, J = 8.4, 7.5 Hz, 1H, 4'-H), 4.39 (dd, J = 8.5, 7.3 Hz, 1H, 4'-H), 4.81 (dt, J = 5.7, 2.7 Hz, 1H, 2'-H), 5.15 (d, J = 3.2 Hz, 1H, 2'-OH), 5.94 (br s, 2H, NH), 5.97 (d, J = 2.6 Hz, 1H, 1'-H), 7.94 (s, 1H, 8-H), 8.32 (s, 1H, 2-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.52 (SiCH₃), -5.50 (SiCH₃), 18.2 (*C*(CH₃)₃), 25.8 (C(CH₃)₃), 43.3 (3'-C), 60.0 (5'-C), 71.2 (4'-C), 77.1 (2'-C), 93.0 (1'-C), 120.3 (5-C), 138.4

(8-C), 149.0 (4-C), 152.7 (2-C), 155.5 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₆H₂₈N₅O₃Si 366.1961; Found 366.1941.

1'-(Thymin-1-yl)-3'-deoxy-5'-*O*-(*tert*-butyldimethylsilyl)-β-D-apio-D-furanose (51): Following a similar procedure described for compound **49**, compound **2a** (200 mg, 0.83 mmol) afforded compound **51** (260 mg, 88%) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.05 (s, 6H, Si(CH₃)₂), 0.87 (s, 9H, C(CH₃)₃), 1.92 (d, J = 1.2 Hz, 3H, 5-CH₃), 2.51 - 2.66 (m, 1H, 3'-H), 3.69 (dd, J = 10.5, 6.2 Hz, 1H, 5'-H), 3.75 (dd, J = 10.3, 4.7 Hz, 1H, 5'-H), 3.94 - 4.07 (m, 2H, 4'-H & 2'-OH), 4.18 (ddd, J = 7.0, 4.0, 2.8 Hz, 1H, 2'-H), 4.28 (t, J = 8.4 Hz, 1H, 4'-H), 5.61 (d, J = 4.1 Hz, 1H, 1'-H), 7.27 (d, J = 1.2 Hz, 1H, 6-H), 9.42 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.40, -5.35 (SiCH₃), 12.7 (5-CH₃), 18.3 (C(CH₃)₃), 25.9 (C(CH₃)₃), 48.4 (3'-C), 60.8 (5'-C), 71.0 (4'-C), 78.7 (2'-C), 94.4 (1'-C), 110.7 (5-C), 134.9 (6-C), 151.7 (2-C), 164.1 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₆H₂₉N₂O₅Si 357.1846; Found 357.1855.

1'-(Adenin-9-yl)-3'-deoxy-5'-*O*-(*tert*-butyldimethylsilyl)-β-D-apio-D-furanose (52):

Following a similar procedure described for compound **49**, compound **2b** (350 mg, 1.39 mmol) afforded compound **52** (415 mg, 82%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.03, 0.04 (s's, 2 x 3H, Si(CH₃)₃), 0.85 (s, 9H, C(CH₃)₃), 2.64 - 2.79 (m, 1H, 3'-H), 3.76 (dd, *J* = 10.4, 6.3 Hz, 1H, 5'-H), 3.85 (dd, *J* = 10.4, 4.5 Hz, 1H, 5'-H), 4.15 (t, *J* = 9.1 Hz, 1H, 4'-H), 4.30 - 4.40 (t, *J* = 8.5 Hz, 1H, 4'-H), 4.52 (dd, *J* = 8.6, 5.7 Hz, 1H, 2'-H), 5.69 (br.s, 1H, 2'-OH), 5.79 (d, *J* = 5.9 Hz, 1H, 1'-H), 5.95 (s, 2H, NH₂), 7.97 (s, 1H, 8-H), 8.27 (s, 1H, 2-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.53, -5.49 (SiCH₃), 18.2 (*C*(CH₃)₃), 25.8 (C(CH₃)₃), 47.7 (3'-C), 61.1 (5'-C), 71.1 (4'-C), 77.4 (2'-C), 92.8 (1'-C), 120.1 (5-C), 138.4 (8-C), 149.2 (4-C), 152.5 (2-C), 155.5 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₆H₂₈N₅O₃Si 366.1961; Found 366.1962.

1'-(Thymin-1-yl)-2',3'-dideoxy-5'-O-benzyl-α-D-apio-L-furanose (53): To a solution of compound 37 (250 mg, 0.75 mmol) and DMAP (184 mg, 1.5 mmol) in acetonitrile (10 mL) was added dropwise O-p-tolyl chlorothionoformate (138µL, 0.9 mmol) at room temperature. The mixture was stirred for additional 2h, and then the volatile organics were evaporated under reduced pressure. The residue was suspended in EtOAc and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate and the solvent evaporated to dryness. The residue obtained was suspended in toluene (25 mL), tributyltinhydride (0.51 mL, 1.88 mmol) was added followed by at 60-70 °C was added azoisobutyronitrile (AIBN, 250 mg, 1.5 mmol) and heated to 110-120 °C for 3h. Volatile materials were evaporated and the residue was purified by silica-gel flash column chromatography using 0.5-2% MeOH-CH₂Cl₂ to afford compound **53** (167 mg, 70 %) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.86 (d, J = 1.2 Hz, 3H, 5-CH₃), 2.06 (ddd, J = 13.8, 7.9, 3.8 Hz, 1H, 2'-H), 2.16 (ddd, J = 13.8, 7.5, 6.4 Hz, 1H, 2'-H), 2.52 - 2.68 (m, 1H, 3'-H), 3.36 (dd, J = 9.1, 7.3 Hz, 1H, 5'-H), 3.45 (dd, J = 9.1, 5.6 Hz, 1H, 5'-H), 3.74 (dd, J = 8.8, 7.0 Hz, 1H, 4'-H), 4.24 (dd, J = 8.8, 7.3 Hz, 1H, 4'-H), 4.45 (s, 2H, CH₂Ph), 5.96 (dd, J = 6.4, 4.1 Hz, 1H, 1'-H), 7.07 (d, J =1.2 Hz, 1H, 6-H), 7.20 - 7.33 (m, 5H, CH₂Ph), 8.56 (br s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.7 (5-CH₃), 35.9 (2'-C), 38.1 (3'-C), 70.8 (5'-C), 72.7 (4'-C), 73.4 (CH₂Ph), 87.0 (1'-C), 110.4 (5-C), 127.7 (CH₂Ph), 127.9 (CH₂Ph), 128.5 (CH₂Ph), 135.0 (6-C), 137.8 (CH₂*Ph*), 150.1 (2-C), 163.7 (4-C). HRMS (ESI-TOF) m/z: $[M + H]^+$ Calcd for C₁₇H₂₁N₂O₄ 317.1501; Found 317.1499.

1'-(Adenin-9-yl)-2',3'-dideoxy-5'-*O***-benzyl-α-D-apio-L-furanose (54):** Following a similar procedure described for compound **53**, compound **38** (45 mg, 0.13 mmol) gave compound **54** (30 mg, 70 %) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.32 (ddd (dt), *J* = 13.9, 7.1 Hz, 1H, 2'-H), 2.68 (ddd, *J* = 13.6, 7.8, 2.9 Hz, 1H, 2'-H), 2.81 - 2.95 (m, 1H, 3'-H), 3.45 - 3.58 (m, 2H, 5'-H), 3.90 (dd, *J* = 8.8, 6.4 Hz, 1H, 4'-H), 4.34 (dd, *J* = 8.6, 7.5 Hz, 1H, 4'-

H), 4.53 (s, 2H, CH₂Ph), 6.11 (br s, 2H, NH), 6.29 (dd, J = 6.9, 3.1 Hz, 1H, 1'-H), 7.27 - 7.39 (m, 5H, CH₂Ph), 7.90 (s, 1H, 8-H), 8.32 (s, 1H, 2- H). ¹³C NMR (75 MHz, CDCl₃) δ ppm 35.5 (2'-C), 38.2 (3'-C) 71.0 (5'-C), 72.2 (4'-C), 73.3 (CH₂Ph), 85.9 (1'-C), 120.2 (5-C), 127.6 (CH₂Ph), 127.8 (CH₂Ph), 128.4 (CH₂Ph), 137.9 (CH₂Ph), 138.5 (8-C), 149.2 (4-C) 152.8 (2-C) 155.5 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₇H₂₀N₅O₂ 326.1617; Found 326.1611.

1'-(Thymin-1-yl)-2',3'-dideoxy-5'-O-(tert-butyldimethylsilyl)-α-D-apio-L-furanose

(55)^[3]: Following a similar procedure described for compound **53**, compound **49** (190 mg, 0.53 mmol) gave compound **55** (130 mg, 72 %) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.06 (s, 6H, Si(CH₃)₂), 0.90 (s, 9H, C(CH₃)₃), 1.94 (d, *J* = 1.3 Hz, 3H, 5-CH₃), 2.06 (ddd, *J* = 13.8, 8.2, 4.0 Hz, 1H, 2'-H), 2.25 (dt, *J* = 13.8, 6.9 Hz, 1H, 2'-H), 2.48 - 2.63 (m, 1H, 3'-H), 3.58 (dd, *J* = 10.0, 6.8 Hz, 1H, 5'-H), 3.66 (dd, *J* = 10.1, 5.2 Hz, 1H, 5'-H), 3.83 (dd, *J* = 8.8, 6.9 Hz, 1H, 4'-H), 4.26 (dd, *J* = 8.7, 7.2 Hz, 1H, 4'-H), 6.04 (dd, *J* = 6.6, 3.9 Hz, 1H, 1'-H), 7.16 (q, *J* = 1.3 Hz, 1H, 6-H), 8.88 (br s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.51 (SiCH₃), -5.48 (SiCH₃), 12.7 (5-CH₃), 18.2 (*C*(CH₃)₃), 25.8 (C(CH₃)₃), 35.3 (2'-C), 40.1 (3'-C), 63.4 (5'-C), 72.2 (4'-C), 87.1 (1'-C), 110.4 (5-C), 135.1 (6-C), 150.2 (2-C), 163.9 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₆H₂₉N₂O₄Si 341.1897; Found 341.1884.

1'-(Adenin-9-yl)-2',3'-dideoxy-5'-*O*-(*tert*-butyldimethylsilyl)-α-D-apio-L-furanose (56)^[3]: Following a similar procedure described for compound 53, compound 50 (300 mg, 0.82 mmol) gave compound 56 (253 mg, 88 %) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.07 (s, 6H, Si(CH₃)₂), 0.91 (s, 9H, C(CH₃)₃), 2.34 (ddd (dt), J = 13.7, 7.1 Hz, 1H, 2'-H), 2.62 (ddd, J = 13.3, 7.8, 2.9 Hz, 1H, 2'-H), 2.76 (dq, J = 13.5, 6.9 Hz, 1H, 3'-H), 3.60 - 3.74 (m, 2H, 5'-H), 3.92 (dd, J = 8.8, 6.4 Hz, 1H, 4'-H), 4.31 (dd, J = 8.5, 7.3 Hz, 1H, 4'-H),

5.70 (br s, 2H, NH), 6.30 (dd, J = 6.7, 2.9 Hz, 1H, 1'-H), 7.93 (s, 1H, 8-H), 8.36 (s, 1H, 2-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.45 (Si(CH₃)), -5.42 (Si(CH₃)), 18.3 (*C*(CH₃)₃), 25.8 (C(*C*H₃)₃), 34.9 (2'-C), 40.4 (3'-C), 63.5 (5'-C), 71.8 (4'-C), 86.1 (1'-C), 120.3 (5-C), 138.6 (8-C), 149.4 (4-C), 153.0 (2-C), 155.4 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₆H₂₈N₅O₂Si 350.2012; Found 350.2006.

1'-(Thymin-1-yl)-2',3'-dideoxy-5'-(*tert*-butyldimethylsilyl)-β-D-apio-D-furanose (57)^[3]: Following a similar procedure described for compound **53**, compound **51** (250 mg, 0.70 mmol) gave compound **57** (215 mg, 90 %) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.06 (s, 6H, SiC*H*₃), 0.89 (s, 9H, C(C*H*₃)₃), 1.77 (ddd, *J* = 13.3, 8.9, 7.2 Hz, 1H, 2'-H), 1.94 (d, *J* = 1.2 Hz, 3H, 5-CH₃), 2.43 - 2.55 (m, 1H, 2'-H), 2.55 - 2.72 (m, 1H, 3'-H), 3.60 (dd, *J* = 10.3, 5.9 Hz, 1H, 5'-H), 3.67 (dd, *J* = 10.3, 5.0 Hz, 1H, 5'-H), 3.94 (t, *J* = 7.8 Hz, 1H, 4'-H), 4.07 (t, *J* = 8.1 Hz, 1H, 4'-H), 6.06 (dd, *J* = 7.0, 6.4 Hz, 1H, 1'-H), 7.21 (q, *J* = 1.2 Hz, 1H, 6-H), 8.31 (br.s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.47, -5.44 (SiCH₃), 12.6 (5-CH₃), 18.3 (*C*(CH₃)₃), 25.8 (C(CH₃)₃), 34.6 (2'-C), 40.9 (3'-C), 62.6 (5'-C), 71.0 (4'-C), 86.6 (1'-C), 110.9 (5-C), 134.9 (6-C), 150.3 (2-C), 163.8 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₆H₂₉N₂O₄Si 341.1897; Found 341.1891.

1'-(Adenin-9-yl)-2',3'-dideoxy-5'-(*tert***-butyldimethylsilyl)**-β**-D-apio-D-furanose** (**58**)^[3]: Following a similar procedure described for compound **53**, compound **52** (400 mg, 1.10 mmol) gave compound **58** (310 mg, 81 %) as a white foam. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.05 (s, 6H, SiCH₃), 0.88 (s, 9H, C(CH₃)₃), 2.33 - 2.50 (m, 1H, 2'-H), 2.57 - 2.81 (m, 2H, 2' & 3'-H's), 3.71 (d, J = 5.3 Hz, 2H, 5'-H), 4.04 (t, J = 8.2 Hz, 1H, 4'-H), 4.14 (t, J = 7.6 Hz, 1H, 4'-H), 5.82 (br.s, 2H, NH₂), 6.29 (t, J = 5.9 Hz,1H, 1'-H), 8.05 (s, 1H, 8-H), 8.36 (s, 1H, 2-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.44 (SiCH₃), 18.3 (*C*(CH₃)₃), 25.9 (C(*C*H₃)₃), 34.6 (2'-C), 41.6 (3'-C), 63.0 (5'-C), 71.1 (4'-C), 85.5 (1'-C), 120.2 (5-C), 138.4 (8-C), 149.7 (4-

C), 153.0 (2-C), 155.5 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₆H₂₈N₅O₂Si 350.2012; Found 350.2009.

1'-(Thymin-1-yl)-2',3'-dideoxy-α-D-apio-L-furanose (4a)^[3]: Following the hydrogenation procedure described for compound **5a**, compound **53** (150 mg, 0.47 mmol) gave compound **4a** (80 mg, 63 %) as a white solid. Alternatively, compound **55** (110 mg, 0.32 mmol) was dissolved in THF (2 mL) and TBAF (1M, 0.65 mL, 0.65 mmol) was added at room temperature. The reaction mixture was stirred for 3h, solvents evaporated, and the residue was subjected to silica-gel flash column chromatography (4-5% MeOH-CH₂Cl₂) to afford **4a** (65 mg, 89%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.80 (d, *J* = 0.9 Hz, 3H, 5-CH₃), 1.96 - 2.13 (m, 2H, 2'-H), 2.45-2.60 (m, 1H, 3'-H), 3.33 - 3.48 (m, 2H, 5'-H), 3.63 (dd, *J* = 8.2, 6.2 Hz, 1H, 4'-H), 4.22 (dd, *J* = 8.2, 7.0 Hz, 1H, 4'-H), 4.76 (t, *J* = 5.3 Hz, 1H, 5'-OH), 5.97 (dd, *J* = 6.4, 4.7 Hz, 1H, 1'-H), 7.43 (d, *J* = 1.2 Hz, 1H, 6-H), 11.24 (s, 1H, NH). ¹³C NMR (75 MHz, CD₃OD) δ ppm 12.6 (5-CH₃), 36.2 (2'-C), 41.7 (3'-C), 63.9 (5'-C), 73.3 (4'-C), 88.5 (1'-C), 111.4 (5-C), 137.9 (6-C), 152.4 (2-C), 166.7 (4-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₅N₂O₄ 227.1032; Found 227.1041.

1'-(Adenin-9-yl)-2',3'-dideoxy-α-D-apio-L-furanose (4b)^[3]: Compound **56** (350 mg, 1.0 mmol) was dissolved in MeOH (15 mL) in a polypropylene vessel and NH₄F (742 mg, 20 mmol) was added at room temperature. The reaction mixture was stirred at 55 °C for 48h; CH₂Cl₂ (20 mL) was added to the reaction vessel and filtered. The filtrate was evaporated, and the residue was subjected to silica-gel flash column chromatography (10-12% MeOH-CH₂Cl₂) to afford **4b** (205 mg, 87%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.21 (app-q, J = 6.7, 13.5 Hz, 1H, 2'-H), 2.54 (ddd, J = 3.5, 8.2, 12.9 Hz, 1H, 2'-H), 2.76 (sep, J = 6.4 Hz, 1H, 3'-H), 3.44 (m, 2H, 5'-H), 3.75 (dd, J = 5.3, 8.2 Hz, 1H, 4'-H), 4.18 (t, J = 7.9 Hz, 1H, 4'-H), 4.82 (t, J = 5.0 Hz, 1H, 5'-OH), 6.27 (dd, J = 3.2, 6.7 Hz, 1H, 1'-H),

7.24 (br s, 2H, 6-NH₂'s), 8.15 (s, 1H, 2-H), 8.26 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO- d_6) 33.9 (2'-C), 40.4 (3'-C), 62.2 (5'-C), 70.9 (4'-C), 84.3 (1'-C), 119.2 (5-C), 139.2 (8-C), 148.9 (4-C), 152.5 (2-C), 156.0 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₄N₅O₂ 236.1147; Found 236.1131.

1'-(Thymin-1-yl)-2',3'-dideoxy-β-D-apio-D-furanose (1a)^[3]: Following a similar procedure described for the synthesis of compound **4b**, compound **57** (200 mg, 0.59 mmol) gave compound **1a** (115 mg, 86 %) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.71 (t, J = 4.7 Hz, 1H, 5'-OH), 1.74 - 1.86 (m, 1H, 2'-H), 1.94 (d, J = 1.5 Hz, 3H, 5-CH₃), 2.51 - 2.75 (m, 2H, 2' & 3'-H's), 3.64 - 3.81 (m, 2H, 5'-H), 3.98 (dd, J = 8.8, 7.0 Hz, 1H, 4'-H), 4.07 - 4.16 (m, 1H, 4'-H), 6.02 (t, J = 6.6 Hz, 1H, 1'-H), 7.27 - 7.30 (q, J = 1.4 Hz, 1H, 6-H), 8.43 (br.s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 12.6 (5-CH₃), 34.7 (2'-C), 40.7 (3'-C), 63.2 (5'-C), 71.2 (4'-C), 86.9 (1'-C), 110.8 (5-C), 135.3 (6-C), 150.3 (2-C), 163.6 (4-C). HRMS (ESI-TOF) m/z: [M - H]⁻ Calcd for C₁₀H₁₃N₂O₄ 225.0881; Found 225.0875.

1'-(Adenin-9-yl)-2',3'-dideoxy-α-D-apio-D-furanose (1b)^[3]: Following a similar procedure described for the synthesis of compound **4b**, compound **58** (300 mg, 0.86 mmol) gave compound **1b** (190 mg, 94 %) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.25 - 2.39 (m, 1H, 2'-H), 2.52 - 2.67 (m, 2H, 2' & 3'-H's), 3.48 - 3.65 (m, 2H, 5'-H), 3.89 (t, J = 8.2 Hz, 1H, 4'-H), 4.00 (t, J = 7.9 Hz, 1H, 4'-H), 4.82 (t, J = 5.1 Hz, 1H, 5'-OH), 6.23 (t, J = 6.7 Hz, 1H, 1'-H), 7.26 (s, 2H, NH₂), 8.15 (s, 1H, 2-H), 8.32 (s, 1H, 8-H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 33.7 (2'-C), 41.7 (3'-C), 61.7 (5'-C), 70.8 (4'-C), 84.3 (1'-C), 119.2 (5-C), 139.1 (8-C), 149.2 (4-C), 152.5 (2-C). 156.0 (6-C). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₀H₁₄N₅O₂ 236.1147; Found 236.1137.

1'-(Adenin-9-yl)-2',3'-dideoxy-β-D-apio-D-furanose triphosphate (12): Compound **1b** (25 mg, 0.106 mmol) and tributylammonium pyrophosphate **60** (117 mg, 0.212 mmol) were

placed in a 50 mL and a 10 mL RB flask respectively, and dried under high vacuum for 1h. 2chloro-4H-1,3,2-benzodioxaphosphinin-4-one 59 (43 mg, 0.212 mmol) was placed in a separate 10 mL flask and dried briefly (10 min) under high vacuum. Anhydrous DMF (0.25 mL) was added to each flask under argon atmosphere. Tributylamine (dried and stored over 4A molecular sieves, 0.3 mL) was added to the flask containing tributylammonium pyrophosphate (60) with stirring. The contents of this flask were added to the flask containing 2-chloro-4H-1,3,2-benzodioxaphosphinin-4-one (59) and stirring continued for 1.5h. The cyclic phosphitodiphosphate (61) formed was added to a flask containing compound 4b in DMF. After stirred for 1.5h, 3% iodine solution (9:1 pyridine-water, 2.25 mL) was added drop wise and stirred for 20 min followed by the addition of water (4 mL) and stirred for additional 1.5h. 3M NaCl solution (0.66 mL) was added to the reaction mixture. The reaction mixture was transferred to two centrifuge tubes (~4 mL each) and absolute ethanol (16 mL) was added to each tube, shaken well and immersed in powdered dry ice for 1h. The tubes were centrifuged (20 °C, 3200 rpm, 20 min), and the clear solution decanted to afford crude product as white solid. The crude product was dissolved in distilled water (3.0 mL) and purified using Source-15Q ion exchange HPLC (0.5 mL injection, $0 \rightarrow 5$ min, 100% H₂O; $5 \rightarrow 40$ min, 100% H₂O to 100% 1M triethylammonium bicarbonate buffer, linear gradient @flow rate 6 mL/min). The compound eluting at 33 min (or 0.8M triethylammonium bicarbonate buffer) was collected and lyophilized to afford triethylammonium salt of triphosphate **12** as a white solid (17 mg, 21%) as highly hygroscopic colorless solid. ¹H NMR (300 MHz, D_2O) δ ppm 1.27 (t, J = 7.3 Hz, 24H, NCH₂CH₃), 1.33 (t, J = 7.3 Hz, 3H, NCH₂CH₃), 2.42 (ddd, J = 13.6, 8.6, 6.7 Hz, 1H, 2'-H), 2.74 - 2.89 (m, 1H, 2'-H), 2.89 - 3.12 (m, 3H, 3'-H & NCH₂CH₃), 3.19 (q, J = 7.3 Hz, 14H, NCH₂CH₃), 3.54 (q, J = 7.1 Hz, 2H, NCH₂CH₃), 4.05 (t, J = 8.6 Hz, 1H, 4'-H), 4.14 (app-t, J = 6.2 Hz, 2H, 5'-H), 4.28 (t, J = 8.5 Hz, 1H, 4'-H), 6.35 (t, J = 6.7 Hz, 1H, 1'-H), 8.26 (s, 1H), 8.47 (s, 1H). ¹³C NMR (75 MHz,

D₂O) δ ppm 7.3, 8.4, 10.7 (NCH₂*C*H₃), 33.6 (2'-C), 39.3 (d, $J_{p-c} = 8.1$ Hz, 3'-C), 42.4, 46.8 (NCH₂CH₃), 66.3 (d, $J_{p-c} = 5.9$ Hz, 5'-C), 70.8 (4'-C), 85.1 (1'-C), 150.8, 154.3. ³¹P NMR (121 MHz, D₂O) δ ppm -23.28 (br.s, 1P, β-P) -11.20, -11.04 (br. d, 2P, α & γ-P). HRMS (ESI-TOF) m/z: [M - H]⁻ Calcd for C₁₀H₁₅N₅O₁₁P₃ 473.9986; Found 473.9987.

1'-(Adenin-9-yl)-2',3'-dideoxy-α-D-apio-L-furanose triphosphate (13): Following the reaction protocol described for the synthesis of **12**, compound **4b** (25 mg, 0.106 mmol) afforded triethylammonium salt of triphosphate **13** as a white solid (45 mg, 48%). ¹H NMR (300 MHz, D₂O) δ ppm 1.21 (t, J = 7.3 Hz, 36H, HN(CH₂CH₃)₃), 2.46 (dt, J = 14.4, 7.3 Hz, 1H, 2'-H), 2.66 (ddd, J = 14.1, 8.1, 3.2 Hz, 1H, 2'-H), 3.10 (q, J = 7.3 Hz, 25H, 3'-H & HN(CH₂CH₃)₃), 3.95 (dd, J = 8.9, 6.3 Hz, 1H, 4'-H), 3.99 - 4.12 (m, 2H, 5'-H), 4.27 (dd, J = 8.8, 7.6 Hz, 1H, 4'-H), 6.37 (dd, J = 7.0, 3.2 Hz, 1 H), 8.16 (s, 1H, 2-H), 8.28 (s, 1H, 8-H). ¹³C NMR (75 MHz, D₂O) δ ppm 8.4 (HN(CH₂CH₃)₃), 33.9 (2'-C), 38.4 (d, $J_{p-c} = 8.3$ Hz, 3'-C), 46.7 (HN(CH₂CH₃)₃), 66.9 (d, $J_{p-c} = 6.1$ Hz, 5'-C), 71.4 (4'-C), 85.3 (1'-C), 119.1 (5-C), 140.2 (8-C) 148.6 (4-C), 152.7 (2-C), 155.7 (6-C). ³¹P NMR (121 MHz, D₂O) δ ppm -22.64 (dd, J = 21.1, 19.6 Hz, βP), -11.04 (d, J = 19.6 Hz, αP), -6.34 (d, J = 21.1 Hz, γP). HRMS (ESI-TOF) m/z: [M - H]⁻ Calcd for C₁₀H₁₅N₅O₁₁P₃ 473.9986; Found 473.9982.

1'-(Thymin-1-yl)-2',3'-dideoxy-\alpha-D-apio-D-furanose [phenyl-(benzoxy-L-alaninyl)] phosphate (9a): To a solution of 1a (0.048 g, 0.21 mmol) in anhydrous THF (4 mL) was added a solution of phosphorochloridate $64a^{[38]}$ (0.22g, 0.64 mmol) in anhydrous THF (2 mL), followed by the drop wise addition, under an argon atmosphere, of anhydrous NMI (0.88 mL, 1.11 mmol) and the reaction mixture was stirred at room temperature for 48 h. After this period, the solvent was removed and the residue taken up in dichloromethane and washed with 0.5 M HCl (2 x 15 mL). The combined organics were dried over MgSO₄ filtered and evaporated. The residue was purified by preparative thin layer chromatography (2000 micron,

Aldrich) using a mixture CH₂Cl₂/MeOH 95:5 v/v as eluent to give 9a (0.040 g, 35%) as a pale yellow foamy solid. ¹H NMR (500 MHz, CD₃OD) δ ppm 7.47, 7.46 (d, J = 2.5 Hz, 2H, H-6), 7.37-7.32 (m, 14H, Ph and CH₂Ph), 7.23-7.18 (m, 6H, Ph), 5.99 (t, J = 6.0 Hz, 1H, H-1'), 5.98 (t, J = 6.0 Hz, 1H, H-1'), 5.17-5.15 (m, 4H, CH₂Ph), 4.17-4.05 (m, 4H, CH₂OP), 4.04-4.01 (m, 2H, CHCH₃), 4.00-3.87 (m, 4H, CH₂O), 2.79-2.73 (m, 1H, H-3'), 2.72-2.66 (m, 1H, H-3'), 2.05-2.39 (m, 2H, H-2'a), 1.89, 1.88 (d, J = 1.5 Hz, 6H, CH₃), 1.81-1.72 (m, 2H, H-2'b), 1.38 (d, J = 7.5 Hz, 3H, CHCH₃), 1.35 (d, J = 7.5 Hz, 3H, CHCH₃). ¹³C NMR (125) MHz, CD₃OD) δ ppm 174.9 (d, $J_{CP} = 5.0$ Hz, CO₂Bn), 174.7 (d, $J_{CP} = 5.0$ Hz, CO₂Bn), 166.44, 166.42 (CO), 152.30, 152.29 (CO), 152.21 (d, J_{CP} = 2.8 Hz, C_{ipso} OPh), 152.16 (d, J_{CP} = 2.8 Hz, C_{ipso}OPh), 137.54, 137.52 (C-6), 137.32, 137.31 (C_{ipso}OCH₂Ph), 130.82, 130.80 (Ph), 129.66, 129.64, 129.43, 129.40, 129.36, 129.31 (CH₂Ph), 126.25, 126.23 (Ph), 121.5 (d, $J_{CP} = 4.6$ Hz, Ph), 121.4 (d, $J_{CP} = 5.3$ Hz, Ph), 111.7 (C-5), 88.07, 88.03, (C-1'), 71.7, 71.5 (CH₂O), 68.4 (d, J_{CP} = 5.0 Hz, CH₂OP), 68.3 (d, J_{CP} = 5.0 Hz, CH₂OP), 68.0 (CH₂Ph), 51.8, 51.6 (CHCH₃), 40.5 (d, J_{CP} = 3.8 Hz, C-3'), 40.4 (d, J_{CP} = 3.8 Hz, C-3'), 35.2, 35.1 (CH₂), 20.4 (d, $J_{CP} = 7.5$ Hz, CHCH₃), 20.3 (d, $J_{CP} = 7.5$ Hz, CHCH₃), 12.5 (CH₃). ³¹P NMR (202 MHz, CD₃OD) δ ppm 3.88, 3.33. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₆H₃₀N₃O₈PNa 566.1668; Found 566.1663. HPLC; ACN/H₂O 10/90 v/v to 100/0 in 30 min, $\lambda = 280$ nm, flow 1 mL/min, t_R = 15.42 min.

1'-(Adenin-9-yl)-2',3'-dideoxy-α-D-apio-D-furanose [phenyl-(benzoxy-L-alaninyl)] phosphate (9b): Following the reaction protocol mentioned for the synthesis of compound 9a, 1b (0.050 g, 0.21 mmol) was reacted with phosphorochloridate 64a (0.23 g, 0.66 mmol) to give 9b (0.030 g, 26%) as a white foamy solid. ¹H NMR (500 MHz, CD₃OD) δ ppm 8.24, 8.23 (2s, 1H, H-8), 8.22, 8.21 (2s, 1H, H-2), 7.40-7.26 (m, 16H, Ph), 7.22-7.15 (m, 4H, Ph), 6.27 (t, J = 7.0 Hz, 1H, H-1'), 6.24 (t, J = 6.5 Hz, 1H, H-1'), 5.14 (s, 4H, CH₂Ph), 4.26-4.19 (m, 4H CH₂OP), 4.10-3.96 (m, 6H, CH₂O and CHCH₃), 2.91-2.75 (m, 2H, H-3'), 2.69- 2.57 (m, 2H, H2'a), 2.41-2.34 (m, 2H, H2'b), 1.37 (d, J = 6.5 Hz, 3H, CH₃), 1.35 (d, J = 7.0 Hz, 3H, CH₃). ¹³C NMR (125 MHz, CD₃OD) δ ppm 175.0 (d, $J_{CP} = 4.2$ Hz, CO₂Bn), 174.7 (d, $J_{CP} = 4.6$ Hz, CO₂Bn), 157.3 (C-6), 153.84, 153.83 (C-2), 152.22 (d, $J_{CP} = 2.5$ Hz, C_{ipso}OPh), 152.17 (d, $J_{CP} = 2.5$ Hz, C_{ipso}OPh), 150.4 (C-4), 140.78, 140.74 (C-8), 137.29, 137.28 (C_{ipso}OCH₂*Ph*), 130.80 (d, $J_{CP} = 0.7$ Hz, Ph), 130.78 (d, $J_{CP} = 0.9$ Hz, Ph), 129.60, 129.38, 129.36, 129.35, 129.30 (CH₂*Ph*), 126.20 (d, $J_{CP} = 1.3$ Hz, Ph), 126.17 (d, $J_{CP} = 1.3$ Hz, Ph), 121.5 (d, $J_{CP} = 4.6$ Hz, Ph), 121.4 (d, $J_{CP} = 4.6$ Hz, Ph), 120.70, 120.68 (C-5), 87.00, 86.98, (C-1'), 71.8, 71.7 (CH₂O), 68.22 (d, $J_{CP} = 5.5$ Hz, CH₂OP), 68.15 (d, $J_{CP} = 5.5$ Hz, CH₂OP), 67.99, 67.97 (*C*H₂Ph), 51.8 (d, $J_{CP} = 1.4$ Hz, *C*HCH₃), 51.7 (*C*HCH₃), 41.10 (d, $J_{CP} = 7.8$ Hz, C-3'), 41.05 (d, $J_{CP} = 7.8$ Hz, C-3'), 35.2, 35.1 (CH₂), 20.4 (d, $J_{CP} = 7.0$ Hz, CHCH₃), 20.3 (d, $J_{CP} = 7.0$ Hz, CHCH₃). ³¹P NMR (202 MHz, CD₃OD) δppm 3.80, 3.28. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₆H₃₀N₆O₆P 553.1964; Found 553.1960 and [M + Na]⁺ Calcd for C₂₆H₂₉N₆O₆PNa 575.1784; Found 575.1770. HPLC; ACN/H₂O 10/90 v/v to 100/0 in 30 min, $\lambda = 280$ nm, flow 1 mL/min, t_R = 14.36 min.

1'-(Thymin-1-yl)-2',3'-dideoxy-α-D-apio-D-furanose [phenyl-(isopropoxy-L-alaninyl)] phosphate (10a): Following the reaction protocol mentioned for the synthesis of compound 9a, 1a (0.050 g, 0.22 mmol) was reacted with phosphorochloridate **64b** (0.203g, 0.66 mmol) to give **10a** (0.096 g, 88%) as a pale yellow foamy solid. ¹H NMR (500 MHz, CD₃OD) δ ppm 7.58, 7.57 (2s, 2H, H-6), 7.45 (d, J = 8.0 Hz, 2H, Ph), 7.44 (d, J = 7.5 Hz, 2H, Ph), 7.33-7.28 (m, 6H, Ph), 6.10 (t, J = 7.0 Hz, 1H, H-1'), 6.08 (t, J = 7.0 Hz, 1H, H-1'), 5.10-5.03 (m, 2H, CH(CH₃)₂), 4.33-4.21 (m, 4H, CH₂OP), 4.16-4.10 (m, 2H, CH₂O), 4.01-3.96 (m, 2H,CH₂O), 3.94-3.89 (m, 2H, CHCH₃), 2.95-2.86 (m, 2H, H-3'), 2.64-2.56 (m, 2H, H-2'a), 1.97 (s, 6H, CH₃), 1.95-1.88 (m, 2H, H-2'b), 1.43 (d, J = 7.5 Hz, 3H, CHCH₃), 1.40 (d, J =6.5 Hz, 3H, CHCH₃), 1.34-1.30 (m, 12H, CH(CH₃)₂). ¹³C NMR (125 MHz, CD₃OD) δ ppm 175.0 (d, $J_{CP} = 5.4$ Hz, CO₂iPr), 174.5 (d, $J_{CP} = 4.5$ Hz, CO₂iPr), 166.46, 166.44 (CO), 152.30

(d, $J_{CP} = 3.6$ Hz, $C_{ipso}OPh$), 152.28 (CO), 152.25 (d, $J_{CP} = 3.6$ Hz, $C_{ipso}OPh$), 137.6 (C-6), 130.84, 130.81, 126.25, 126.23 (Ph), 121.54 (d, $J_{CP} = 4.5$ Hz, Ph), 121.47 (d, $J_{CP} = 5.3$ Hz, Ph), 111.7 (C-5), 88.15, 88.12, (C-1'), 71.7, 71.6 (CH₂O), 70.19, 70.16 (*C*H(CH₃)₂), 68.4 (d, $J_{CP} = 5.4$ Hz, CH₂OP), 68.3 (d, $J_{CP} = 5.4$ Hz, CH₂OP), 51.89, 51.88 (*C*HCH₃), 40.55 (d, $J_{CP} = 3.5$ Hz, C-3'), 40.49 (d, $J_{CP} = 3.6$ Hz, C-3'), 35.3, 35.2 (CH₂), 22.05, 22.03, 21.98, (CH(*C*H₃)₂), 20.6 (d, $J_{CP} = 7.2$ Hz, CH*C*H₃), 20.4 (d, $J_{CP} = 7.2$ Hz, CH*C*H₃), 12.54, 12.52 (CH₃). ³¹P NMR (202 MHz, CD₃OD) δ ppm 3.89, 3.49. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₂H₃₀N₃O₈PNa 518.1668; Found 518.1653. HPLC; ACN/H₂O 10:90 v/v to 100:0 in 30 min.; $\lambda = 280$ nm, flow 1 mL/min, t_R = 13.79, 13.81 min.

1'-(Adenin-9-yl)-2',3'-dideoxy-α-D-apio-D-furanose [phenyl-(isopropoxy-L-alaninyl)] phosphate (10b): Following the reaction protocol mentioned for the synthesis of compound **9a**, **1b** (0.050 g, 0.21 mmol) was reacted with phosphorochloridate **64b** (0.201g, 0.66 mmol) to give **10b** (0.054 g, 51%) as a white foamy solid. ¹H NMR (500 MHz, CD₃OD) δ ppm 8.27, 8.25 (2s, 2H, H-8), 8.23, 8.22 (2s, 2H, H-2), 7.35 (d, J = 8.0 Hz, 2H, Ph), 7.34 (d, J = 7.8 Hz, 2H, Ph), 7.26-7.16 (m, 6H, Ph), 6.29 (t, *J* = 7.0 Hz, 1H, H-1'), 6.28 (t, *J* = 7.0 Hz, 1H, H-1'), 5.02-4.94 (m, 2H, CH(CH₃)₂), 4.33 (m, 4H, CH₂OP), 4.16-4.05 (m, 4H, CH₂O), 3.93-3.88 (m, 2H, CHCH₃), 2.96-2.89 (m, 2H, H-3'), 2.75- 2.66 (m, 2H, H2'a), 2.49-2.43 (m, 2H, H2'b), 1.35 (d, J = 7.0 Hz, 3H, CH₃), 1.33 (d, J = 7.0 Hz, 3H, CH₃), 1.23-1.21 (m, 12H, CH(CH₃)₂). ¹³C NMR (125 MHz, CD₃OD) δ ppm 175.0 (d, J_{CP} = 4.5 Hz, CO₂*i*Pr), 174.5 (d, J_{CP} = 4.5 Hz, CO₂*i*Pr), 157.4 (C-6), 153.9 (C-2), 152.27 (d, *J*_{CP} = 3.4 Hz, C_{ipso}OPh), 152.22 (d, *J*_{CP} = 2.6 Hz, $C_{ipso}OPh$), 150.4 (C-4), 140.82, 140.79 (C-8), 130.81, 126.19, 126.16 (Ph), 121.53 (d, $J_{CP} =$ 5.5Hz, Ph), 121.45 (d, *J*_{CP} = 5.5 Hz,CH Ph), 120.73, 120.70 (C-5), 87.04, 87.04, (C-1'), 71.89, 71.83 (CH₂O), 70.2 (CH(CH₃)₃), 68.3 (d, $J_{CP} = 6.4$ Hz, CH₂OP), 68.2 (d, $J_{CP} = 6.4$ Hz, CH₂OP), 51.9, 51.7 (CHCH₃), 41.2 (d, *J*_{CP} = 7.2 Hz, C-3'), 41.1 (d, *J*_{CP} = 7.2 Hz, C-3'), 35.2, 35.1 (CH₂), 22.00, 21.95, 21.94, (CH(CH₃)₃), 20.6 (d, $J_{CP} = 6.4$ Hz, CHCH₃), 20.4 (d, $J_{CP} =$

6.4 Hz, CH*C*H₃). ³¹P NMR (202 MHz, CD₃OD) δ ppm 3.81, 3.46. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₂H₃₀N₆O₆P 505.1964; Found 505.1960 and [M + Na]⁺ Calcd for C₂₂H₂₉N₆O₆PNa 527.1784; Found 527.1794. HPLC; ACN/H₂O 10/90 v/v to 100/0 in 30 min, $\lambda = 280$ nm, flow 1 mL/min, t_R = 12.61 min.

1'-(Thymin-1-yl)-2',3'-dideoxy-α-D-apio-L-furanose [phenyl-(benzoxy-L-alaninyl)] phosphate (11a): To a solution of 4a (0.095 g, 0.42 mmol) in anhydrous THF (10 mL) was added 1.0M solution of tert-butyl magnesium chloride in THF (0.84 mL, 0.84 mmol) and the reaction mixture was stirred under an argon atmosphere for 30 min. After this period, a solution of 64a (0.30 g, 0.84 mmol) in anhydrous THF (5 mL) was added dropwise and the reaction mixture was stirred at room temperature for 17 h. After this period, the solvent was removed and the residue was purified by column chromatography, gradient elution of CHCl₃/MeOH = 98/2 to 95/5 to give **11a** (0.051 g, 22%) as a white solid. ³¹P NMR (CD₃OD, 202 MHz): δ 3.80, 3.30. ¹H NMR (CD₃OD, 500 MHz): δ 7.40-7.30 (8H, m, H-6, PhO, OCH₂Ph), 7.23-7.18 (3H, m, PhO, OCH₂Ph), 6.01-5.99 (0.5H, m, H-1'), 5.98-5.96 (0.5H, m, H-1'), 5.17, 5.16 (2H, 2s, OCH₂Ph), 4.28-4.21 (1H, m, H-4' of one diastereoisomer), 4.14-4.00 (3H, m, 3'-CH₂, CHCH₃), 3.75-3.69 (1H, m, H-4' of one diastereoisomer), 2.80-2.74 (0.5H, m, H-3' of one diastereoisomer), 2.73-2.66 (0.5H, m, H-3' of one diastereoisomer), 2.22-2.07 (2H, m, H-2'), 1.90 (3H, 2s, 5-CH₃), 1.38 (1.5H, d, J = 7.2 Hz, CHCH₃ of one diastereoisomer), 1.36 (1.5H, d, J = 7.4 Hz, CHCH₃ of one diastereoisomer). ¹³C NMR (CD₃OD, 125 MHz): δ 12.6 (5-CH₃), 20.38 (d, J_{C-P} = 7.2 Hz, CH₃), 20.44 (d, J_{C-P} = 7.2 Hz, CH₃), 35.61, 35.64 (C-2'), 39.73, 39.79 (C-3'), 51.7, 51.8 (CHCH₃), 68.00 (OCH₂Ph), 68.49 (d, $J_{C-P} = 6.0$ Hz, 3'-CH₂), 68.53 (d, $J_{C-P} = 5.8$ Hz, 3'-CH₂), 72.49, 72.54 (C-4'), 88.36, 88.38 (C-1'), 111.30, 111.33 (C-5), 121.50, 121.53, 121.57, 121.61, 126.2, 128.0, 129.33, 129.37, 129.40, 129.42, 129.65, 129.66, 130.8 (arom H), 137.3 Cipso Bn), 137.74, 137.76 (C-6), 152.16, 152.19, 152.23 (C-2, C_{ipso} OPh), 166.5 (C-4), 174.8 (d, $J_{C-P} = 4.6$ Hz, CO), 175.0 (d,

The Journal of Organic Chemistry

 $J_{C-P} = 4.6$ Hz, CO). HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for $C_{26}H_{30}N_3O_8PNa$ 566.1668; Found 566.1651. HPLC = H₂O/ACN from 100/0 to 0/100 in 30 min = retention time 18.24 min; H₂O/MeOH from 100/0 to 0/100 in 30 min = retention time 25.07 min.

1'-(Adenin-9-yl)-2',3'-dideoxy-α-D-apio-L-furanose [phenyl-(benzoxy-L-alaninyl)]

phosphate (11b): To a solution of 4b (0.10 g, 0.42 mmol) in anhydrous THF (10 mL) and anhydrous pyridine (2 mL) was added a solution of 64a (0.45g, 1.26 mmol) in anhydrous THF (5 mL), followed by the addition drop wise under an argon atmosphere of anhydrous NMI (0.10 mL, 1.26 mmol) and the reaction mixture was stirred at room temperature for 24 h. After this period, a solution of 64a (0.30 g, 0.84 mmol) in anhydrous THF (3 mL) and anhydrous NMI (0.07 mL, 0.84 mmol) were added and the reaction mixture was stirred at room temperature for further 24 h. After this period, the solvent was removed and the residue was purified by column chromatography, gradient elution of CH_2Cl_2 , then $CH_2Cl_2/MeOH =$ 98/2 then 96/4 then 90/10 to give a white solid which was triturated with diethyl ether to give **11b** (0.035 g, 15%) as a white solid. ³¹P NMR (CD₃OD, 202 MHz): δ 3.86, 3.31. ¹H NMR (CD₃OD, 500 MHz): δ 8.22, 8.21, 8.20, 8.17 (2H, 4s, H-2, H-8), 7.37-7.16 (10H, m, arom H), 6.31 (0.5H, dd, J = 7.0 Hz, 3.30 Hz, H-1' of one diastereoisomer), 6.26 (0.5H, dd, J = 7.00Hz, 3.20 Hz, H-1' of one diastereoisomer), 5.16, 5.15 (2H, 2s, CH₂Ph), 4.29-4.22 (1H, m, H-4'), 4.18-4.02 (3H, m, CHCH₃, 3'-CH₂), 3.86-3.78 (1H, m, H-4'), 3.03-2.89 (1H, m, H-3'), 2.65-2.56 (1H, m, H-2'), 2.35-2.24 (1H, m, H-2'), 1.39 (1.5H, d, J = 7.0 Hz, CH₃ of one diastereoisomer), 1.37 (1.5H, d, J = 7.2 Hz, CH₃ of one diastereoisomer). ¹³C NMR (CD₃OD, 125 MHz): δ 20.35 (d, $J_{C-P} = 6.7$ Hz, CHCH₃), 20.41 (d, $J_{C-P} = 6.8$ Hz, CHCH₃), 35.38, 35.39 (C-2'), 40.0 (d, $J_{C-P} = 2.7$ Hz, C-3'), 40.1 ($J_{C-P} = 2.8$ Hz, C-3'), 51.7, 51.8 (CHCH₃), 67.95, 67.97 (*C*H₂Ph), 68.6 (d, J_{C-P} = 5.7 Hz, 3'-CH₂), 68.8 (d, J_{C-P} = 5.8 Hz, 3'-CH₂), 72.13, 72.15 (C-4'), 87.0 (C-1'), 120.7, 121.48, 121.52, 121.57, 121.61, 126.18, 126.21, 129.31, 129.35, 129.37, 129.6, 129.7, 130.8 (arom H), 137.3 (C_{ipso} Bn), 140.8 (C-2), 152.19 (d, J_{C-P} =

5.5 Hz, C_{ipso} OPh), 152.25 (d, $J_{C-P} = 4.7$ Hz, C_{ipso} OPh), 153.7, 153.8 (C-8), 157.3 (C-8), 174.8 (d, $J_{C-P} = 4.7$ Hz, CO), 175.0 (d, $J_{C-P} = 4.5$ Hz, CO). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for $C_{26}H_{29}N_6O_6PNa$ 575.1784; Found 575.1778. HPLC = H₂O/ACN from 100/0 to 0/100 in 30 min = retention time 17.05 min.

Acknowledgements

We thank Mr. Izet Karalic, Mrs. Lizette van Berckelaer, Mrs. Leentje Persoons, Mrs. Leen Ingels, Mrs. Sandra Claes, Mrs. Evelyne Van Kerckhove and Mrs. Frieda De Meyer for excellent technical assistance. D.S. thanks the FWO-Flanders (FWO-Vlaanderen) for a postdoctoral mandate. KU Leuven provided support for the antiviral/cytostatic and enzyme testing (GOA 10/014). The 700 MHz equipment of the Interuniversitary NMR Facility was financed by Ghent University, the Free University of Brussels (VUB), and the University of Antwerp via the "Zware Apparatuur" Incentive of the Flemish Government.

Supporting Information

Supporting Information: biological assay procedure, copies of ¹H, ¹³C, ³¹P and 2-D NMR spectra of relevant compounds. This material is available free of charge via the Internet at http://pubs.acs.org/.

References

[1] De Ciercq, E. Annu. Rev. Pharmacol. Ioxicol. 2011, 51, 1-

- [2] Bamford, M. J.; Humber, D. C.; Storer, R. *Tetrahedron Lett.* **1991**, *32*, 271-274.
- [3] Sells, T. B.; Nair, V. *Tetrahedron* **1994**, *50*, 117-138, for spectral data of compounds **57**, **58**, **1a**, **1b** and for enantiomers of compounds **55**, **56**, **4a**, **4b**.
- [4] Nair, V.; Jahnke, T. S. Antimicrob. Agents Chemother. **1995**, *39*, 1017-1029.
- [5] Wu,T.; Froeyen, M.; Kempeneers, V.; Pannecouque, C.; Wang, J.; Busson, R.; De Clercq, E.; Herdewijn, P. *J. Am. Chem. Soc.* **2005**, *127*, 5056–5065.
- [6] Hammerschmidt, F.; Oehler, E.; Polsterer, J.; Zbiral, E.; Balzarini, J.; DeClercq, E. *Liebigs Annalen* **1995**, *3*, 551-558.
- [7] Parikh, D. K.; Watson, R. R. J. Med. Chem. 1978, 21, 706-709.
- [8] Jung, M. E.; Toyota, A.; De Clercq, E.; Balzarini, J. Mon. Chem. 2002, 133, 499-520.
- [9] Doboszewski, B.; Herdewijn, P. *Tetrahedron* **1996**, *52*, 1651-1668.
- [10] Reist, E. J.; Calkins, D. F.; Goodman, L. Branched chain sugars. J. Am. Chem. Soc. 1968, 90, 3852-3857.
- [11] Hammerschmidt, F.; Ohler, E.; Polsterer, J. P.; Zbiral, E.; Balzarini, J.; DeClercq, E. *Liebigs Annalen* **1995**, *1995*, 559-565.
- [12] Cahard, D.; McGuigan, C.; Balzarini, J. *Mini-Rev. Med. Chem.* **2004**, *4*, 371-381.
- [13] Hacker, S. J.; Erion, M. D. J. Med. Chem. 2008, 51, 2328-2345.
- [14] Gallier, F.; Alexandre, J. A. C.; El Amri, C.; Deville-Bonne, D.; Peyrottes, S.; Perigaud, C. *ChemMedChem* **2011**, *6*, 1094-1106.
- [15] Smith III, A. B.; Sulikowski, G. A.; Sulikowski, M. M.; Fujimoto, K. J. Am. Chem. Soc. 1992, 114, 2567-2576.
- [16] Schoning, K.; Scholz, P.; Wu, X.; Guntha, S.; Delgado, G.; Krishnamurthy, R.; Eschenmoser, A. *Helv. Chim. Act.* **2002**, *85*, 4111-4153.
- [17] Huang, Q.; Herdewijn, P. J. Org. Chem. 2011, 76, 3742–3753.
- Jin, D. Z.; Kwon, S. H.; Moon, H. R.; Gunaga, P.; Kim, H. O.; Kim, D.; Chuna, M. W.; Jeong, L. S. *Bioorg. Med. Chem.* 2004, *12*, 1101–1109.
- [19] Ball, D. H.; Carey, F. A.; Klundt, I. L.; Long, Jr. L. *Carbohydr. Res.* **1969**, *10*, 121-128.

- [20] Lee, J.; Lewin, N. E.; Blumberg, P. M.; Marquez, V. E. *Bioorg. Med. Chem.* **1996**, *4*, 1299-1305.
- [21] Scaffidi, A.; Stubbs, K. A.; Dennis, R. J.; Taylor, E. J.; Davies, G. J.; Vocadlo, D. J.; Stick, R. V. Org. Biomol. Chem. 2007, 5, 3013–3019.
- [22] Bussolo, V. D.; Fiasella, A.; Romano, M. R.; Favero, L.; Pineschi, M.; Crotti, P. *Org. Lett.* **2007**, *9*, 4479–4482.
- [23] Nachman, R. J.; Hoenel, M.; Williams, T. M.; Halaska, R. C.; Mosher, H. S. J. Org. Chem. 1986, 51, 4802–4806.
- [24] Purchased from Carbosynth, Compton, Berkshire, UK. The suppliers claim in their website as 1,2;3,5-*O*-diisopropylidene-D-apio-D-furanose but we discovered that it is actually 1,2;3,5-*O*-diisopropylidene-D-apio-L-furanose **21**.
- [25] Lopin, C.; Gautier, A.; Gauhier, G.; Piettre, S. R. J. Am. Chem. Soc. 2002, 124, 14668-14675.
- [26] Toti, K. S.; Derudas, M.; McGuigan, C.; Balzarini, J.; Van Calenbergh, S. *Eur. J. Med. Chem.* **2011**, *46*, 3704-3713.
- [27] Framski, G.; Gdaniec, Z.; Gdaniec, M.; Boryski, J. *Tetrahedron* 2006, 62, 10123– 10129.
- [28] Hiraguchi, K.; Konno, K.; Yamada, K.; Kitagawa, Y.; Nakamura, K. T.; Tanaka, H. *Tetrahedron* **2010**, *66*, 4587-4600.
- [29] Huang, Q.; Herdewijn, P. Eur. J. Org. Chem. 2011, 19, 3450-3457.
- [30] Sniady, A.; Bedore, M. W.; Jamison, T. F. *Angew. Chem. Int. Ed.* **2011**, *50*, 2155 2158.
- [31] Chu, C. K.; Bhadti, V. S.; Doboszewski, B.; Gu, Z. P.; Kosugi, Y.; Pullaiah, K. C.; Van Roey, P. *J. Org. Chem.* **1989**, *54*, 2217-2225.
- [32] Kumamoto, H, Onuma, s.; Tanaka, H.; Dutschman, G. E.; Cheng, Y-C. *Antivir. Chem. Chemother.* **2006**, *17*, 225-234.
- [33] Nencka, R.; Sinnaeve, D.; Karalic, I.; Martins, J.; Van Calenbergh, S. *Org. Biomol. Chem.* **2010**, *8*, 5234-5246.
- [34] Caton-Williams, J.; Smith, M.; Carrasco, N.; Huang, Z. Org. Lett. 2011, 13, 4156-4159.
- [35] McGuigan, C.; Murziani, P.; Slusarczyk, M.; Gonczy, B.; Vande Voorde, J.; Liekens, S.; Balzarini, J. J. Med. Chem. 2011, 54, 7247–7258.
- [36] Pertusati, F.; Serpi, M.; McGuigan, C. Antiviral Chem. Chemother. 2012, 22,181-203.

1 0
2
3
4
5
6
7
8
9
10
11
12
12
10
14
15
16
17
18
19
20
21
22
23
24
25
20
20
21
28
29
30
31
32
33
34
35
36
37
20
20
39
40
41
42
43
44
45
46
47
48
49
50
51
52
52
55
ວ4
55
56
57
58
59
60

[37]	McGuigan, C.; Bourdin, C.; Derudas, M.; Hamon, N.; Hinsinger, K.; Kandil, S.; Madela, K.; Meneghesso, S.; Pertusati, F.; Serpi, M.; Slusarczyk, M.; Chamberlain, S.; Kolykhalov, A.; Vernachio, J.; Vanpouille, C.; Introini, A.; Margolis, L.; Balzarini, J. <i>Eur. J. Med. Chem.</i> 2013 , <i>70</i> 326-340.
[38]	Derudas, M; Carta, D; Brancale, A; Vanpouille, C; Lisco, A; Margolis, L; Balzarini, J; McGuigan, C. <i>J. Med. Chem.</i> 2009 , <i>52</i> , 5520-5530.
[39]	Renders, M.; Emmerechtes, G.; Rozenski, J.; Krecmerova, M.; Holy, A.; Herdewijn,

- P. Angew. Chem. Int. Ed. 2007, 46, 2501-2504.
- [40] Saboulard, D.; Naesens, L.; Cahard, D.; Salgado, A.; Pathirana, R.; Velazquez, S.;McGuigan, C.; De Clercq, E.; Balzarini, J. *Mol. Pharmacol.* **1999**, *56*, 693-704.
- [41] Furman, P. A.; Murakami, E.; Niu, C.; Lam, A. M.; Espiritu, C.; Bansal, S.; Bao, H.; Tolstykh, T.; Steuer, H. M.; Keilman, M.; Zennou, V.; Bourne, N.; Veselenak, R. L.; Chang, W.; Ross, B. S.; Du, J.; Otto, M. J.; Sofia, M. J. Antiviral Res. 2011, 91, 120-132.
- [42] Murakami, E.; Tolstykh, T.; Bao, H.; Niu, C.; Steuer, H. M. M.; Bao, D.; Chang, W.; Espiritu, C.; Bansal, S.; Lam, A. M.; Otto, M. J.; Sofia, M. J.; Furman, P. A. J. Biol Chem. 2010, 285, 34337-34347.
- [43] Pertusati, F.; Hinsinger, K.; Flynn, A. S.; Powell, N.; Tristram, A.; Balzarini, J.; McGuigan, C. *Eur. J. Med. Chem.* **2014**, *78*, 259-68.
- [44] Balzarini, J.; Holy, A.; Jindrich, J.; Naesens, L.; Snoeck, R.; Schols, D.; De Clercq, E. *Antimicrob. Agents Chemother.* **1993**, 37, 332-338.
- [45] Mbairaroua, O.; Ton-That, T.; Tapiero, C. Carbohydr. Res. 1994, 253, 79-99.
- [46] Tronchet, J. M. J.; Tronchet, M. J. Helv. Chim. Acta 1971, 54, 1466-1479.